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Executive Summary
Executive Summary: The subcutaneous Administration of Bortezomib Practice Guideline Project
Problem
Multiple myeloma is the second leading cause of hematological malignancies in the
United States. Bortezomib is a chemotherapy agent effective in the treatment of all stages of
multiple myeloma. Bortezomib administered by the subcutaneous (SC) route is as efficacious as
the intravenous route. However, the literature does not describe how the drug was to be
administered SC. A review of literature was inconclusive on how to administer SC injections and
supported the need to describe how nurses are administering SC injections in order to develop
practice guidelines.
The question guiding this evidence based project was: For oncology nurses in a network
of community clinics will the development of a standardized guideline for the administration of
SC bortezomib compared to absence of a standard guideline result in the implementation of a
standard guideline.
Purpose
The purpose of this evidence based practice improvement project was to develop a
practice guideline for administering SC bortezomib in a network of community oncology clinics.
Goal
The goal was to present the evidence based practice guideline for implementation at a
network of oncology clinics.
Objectives
The objectives for this project included 1) development and administration of the
Subcutaneous Administration of Bortezomib Survey (SABS), 2) development the Subcutaneous
Administration of Bortezomib Practice Guideline, and 3) implementation of the practice
guideline at the network of community oncology clinics.
Plan
Developing and implementing an evidence based practice guideline required
understanding how nurses administer SC bortezomib. A descriptive web based survey was
administered to 43 registered oncology nurses. The questions were based on an extensive review
of the literature on administering SC injections. The information from the survey and literature
were the basis for developing the guideline. The survey results and guidelines were reviewed
with executives from the network for approval and implementation.
Outcomes and Results
The survey results confirmed different techniques were being used when administering
SC bortezomib. Nurses predominantly used and preferred the abdomen for injections,
particularly in clinics with private administration facilities. Purging versus the use of an air
bubble was essentially divided (49% vs. 51%) within the group. There was no relationship
between needle length and angle of insertion (p=0.34). Most nurses injected over three to five
seconds. Nurses agreed a guideline would be important for improved patient outcomes, and
indicated a willingness to adopt a guideline.
A SC bortezomib injection practice guideline was developed based on the survey results
and evidence from the literature. The final guideline was presented for implementation.
Keywords: DNP capstone project; subcutaneous bortezomib; administration
subcutaneous chemotherapy; subcutaneous injection techniques; oncology nursing.
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Capstone Project

The Subcutaneous Administration of Bortezomib Practice Guideline Capstone Project
was conducted in partial fulfillment of the Regis University, Loretto Heights School of Nursing,
Doctor of Nursing Practice (DNP) program. Capstone projects investigate practice issues and
develop outcomes solutions to improve clinical practice for the benefit of a population
(Zaccagnini & White, 2011). The identified practice issue was the lack of a standardized practice
guideline for administering chemotherapy by the subcutaneous (SC) route. This practice
improvement project was the development of a practice guideline for oncology nurses in a
network of community cancer clinics. The project intended to benefit the patients with multiple
myeloma (MM) who are receiving the chemotherapy, bortezomib, by the SC route.
Problem Recognition and Definition
Purpose
The purpose of this evidence-based practice improvement project was to develop a
practice guideline on the SC administration of the anti-cancer chemotherapy, bortezomib. The
intention of the guideline was to improve oncology nurses’ clinical practice in order to provide
patient with the most relevant evidence based care for optimal outcomes. Oncology nurses who
administered subcutaneous bortezomib (SCB) to patients at the Cancer Clinics of Excellence
(CCE) network of community oncology clinics were asked to complete the Subcutaneous
Administration of Bortezomib Survey (SABS) describing their SCB injection practice. Survey
data and evidence from the clinical literature provided the basis for the practice guideline.
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Problem Statement and Change
Multiple myeloma is the second leading cause of hematologic malignancies in the United
States (US) with an incidence rate of 22,300 and prevalence rate of 77,617 in 2010 (National
Cancer Institute [NCI] 2013). Bortezomib was approved for the treatment of MM by the
intravenous (IV) route in 2003. Numerous studies demonstrate that bortezomib, as a single agent
or in combination with other agents, is highly effective in producing responses and improving
overall survival in patients at all states of MM (Driscoll, Burris & Annunziata, 2012). The United
States (US) Food and Drug Administration (FDA) approved the SC route of administration in
January 2012. However, there is no published information based on clinical studies on how to
administer SCB. There is also a lack of oncology research literature describing how to administer
SC chemotherapy in general. The lack of evidence poses a challenge for oncology nursing
practice. Nurses may be using different techniques for SCB injections. The clinical practice
problem is that inconsistent injection techniques can result in patients experiencing injection site
reactions and pain, whereas good techniques can reduce these adverse events (Girouard &
Theoret, 2008; McEwan et al., 2010). Injection site reactions and pain can be troublesome for
patients and may result in patients choosing to stop effective treatment (Kurtin, Knop &
Millireon, 2012; McEwan et al. 2010).
Nursing sensitive patient outcomes (NSPO) are those patient outcomes that can be
directly impacted by nursing interventions. The anticipated practice change associated with
implementation of the evidence-based guideline will be consistent techniques used by all nurses
in the CCE network when administering SCB. This practice change supports the oncology
nursing sensitive outcomes of providing quality nursing care to minimize adverse events and
maximize effective therapy (Given & Sherwood, 2005).
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Population, Intervention, Comparison, Outcome Practice Question
A practice question addresses the population or problem (P), the proposed intervention
(I), the comparison intervention (C) and the expected outcome of the intervention (O). Houser
(2008) summarizes these elements as the PICO question. The clinical practice problem led to the
following PICO question: (P) For oncology nurses in the Cancer Clinics of Excellence network
of community clinics, (I) will the development of an standardized guideline for the
administration of subcutaneous bortezomib (C) compared to the absence of a guideline (O) result
in the implementation of the guideline?
Project Significance, Scope, and Rationale
The FDA approved the SC administration of bortezomib based on Phase II and Phase III
randomized controlled trials (RCT) demonstrating equal efficacy when compared to IV
administration. Data demonstrated the SC route reduced the incidence of peripheral neuropathy
(PN) experienced by patient compared to the IV route (38% vs. 53%). Dose reductions due to
adverse events were also lower in patients receiving SCB compared to IV (31% vs. 43%)
(Moreau et al., 2011, VELCADE 2012). The implications of dose reductions and stopping
therapy due to adverse events such as PN can include treatment failure or being changed to less
effective therapy (McEwen et al, 2010).
Peripheral neuropathy is the most troubling adverse event associated with IV bortezomib
and can significantly impact patient well-being. Assessing and managing PN is difficult. Results
from an exploratory cross sectional survey of oncology nurses indicated a lack of knowledge,
confidence, training, and proficiency in evaluating patients for chemotherapy induced PN
(Binner, Ross & Browner, 2011). Therefore, reducing or mitigating PN by using the SC route
can improve nursing practice and patient outcomes.
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The scope of the project was to develop a practice guideline for the administration of
SCB and present it to CCE for implementation. In order to develop a practice guideline, the
literature recommends surveying nurses to describe how nurses actually administer SC injections
particularly in oncology and palliative care settings (Annerson & Willman, 2005; Kurtin, Knop
& Milliron, 2012; Walker, Lane & McKenzie, 2010). Therefore, the SABS was administered to
elicit how network oncology nurses were administering SCB. Educating the network nurses on
the guideline to ensure adoption and adherence was not within the scope of the project due to
time constraints and limiting the focus of the project.
Theoretical Foundation
The Theory of Planned Behavior. The Theory of Planned Behavior (TPB) (Ajzen,
2012) asserts that three types of beliefs guide behavior (Figure 1):
•

Behavioral beliefs, or attitudes about current behavior

•

Subjective beliefs, or expectations of others about behavior

•

Control beliefs, or perceived competence of and control over the behavior

The combination of attitude about the behavior, expectations of others and competence
can lead to behavior intentions. The TPB conceptual model provided the basis for developing
SABS questions to assess nurses’ current practice and perceptions.
The SABS was a 44-item instrument. Twenty-two competence questions (control)
identified how nurses are currently preparing and administering SCB injections. Six
demographic questions plus ten opinion questions (behavior) explored what nurses think about
various aspects of SC treatments. Six perception (subjective) questions ascertained how others
might influence SC treatment beliefs. This combination of information about nurses’
competence, perceptions and opinions about practice provided insights into intention to adopt a
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practice guideline (Cote, Cagnon, Houme, Abdeljelil, & Cagnon, 2012; Nirenberg, Reame, Cato,
& Larson, 2010; O’Boyle, Henley, & Larson, 2001; Phansalker, Weir, Morris, & Warner, 2008;
Zhou, Stoltzfus, Houldin, Marks, & Swan, 2010).
Figure 1 The Theory of Planned Behavior

Subjective beliefs:
Perception about
practice and
expectations of
colleagues and
patients
Control belief:
competence and
confidence in
technique used

Behavioral beliefs:
Opinion of current
practice

Behavior:Use
of standard
guidelines to
administer SC
bortezomib

Figure 1. Theory of Planned Behavior conceptual model applied to Capstone Project.
Control, behavior and subjective beliefs influence the intention to implement a practice
guideline. Adapted from "TBP Diagram” by I. Ajzan, 2006. Retrieved from
http://people.umass.edu/aizen/tpb.diag.html. Copyright 2006 by Icek Ajzen. Used and adapted
with permission.
Nursing theoretical framework. Joann Duffy’s Quality Caring Model contends
professional nursing practice is evaluated on an ongoing basis, and competency can be assessed
through self-evaluations. The purposes of the model are to “(1) guide professional practice and
(2) provide a foundation for nursing research” (Duffy, 2010, p. 405). Nurses are responsible for
using evidence in practice and applying attitudes and behaviors of caring. Improvements in
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health outcomes are possible when caring relationships are integrated into nursing practice.
Nurses engage in collaborative relationships with health care teams and independent
relationships with patients and families. Patients may feel cared for when nursing practice is
based on relationship-centered professional encounters and practice is grounded in evidence.
Clinicians can influence patient perceptions about cancer treatment through communication of
data in ways patients can understand and apply to their own situation (Weeks et al., 2012).
The Quality Caring Model is aligned with tenants of the advanced practice Doctor of
Nursing role to improve health care outcomes including:
•

The scientific and theoretical underpinnings for practice

•

Systems and organizations

•

Evidence based practice

•

Interprofessional collaboration

•

Research collaboration

Evidence based practice decision-making includes evidence from the literature,
environmental and organizational context, practitioner experience, and patient preferences
(Brown, Fielding, & Maylahn, 2009). Nurses may be relying on past experiences or other nurses
rather than evidence for SC injection techniques (Squires, Moralejo, & LeFort, 2007).
Addressing only the techniques of nursing skills was inadequate to design a practice guideline;
knowledge and caring attitudes need to be integrated (Bjork & Kirkevold, 2000). The survey
instrument evaluated practice techniques and experience through self-evaluation. The SABS
considered interprofessional collaboration, patient preference and organizational context by
exploring behavioral and subjective beliefs. The SABS questions were supported by the clinical
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literature. The project was in collaboration with individuals involved in research and may
generate hypothesis for future clinical trials.
The results from the SABS and best evidence guided the development of a standard
administration practice guideline. The expected outcome of the guideline is practice
improvement. Multiple myeloma patients receiving SCB may experience decreased site injection
discomfort and feel more confident in nurses’ expertise when the same techniques are being
utilized.
Literature Selection
The primary topics for the literature search included studies on subcutaneous
chemotherapy, SC administration techniques for any drugs and biologics, adherence to practice
guidelines and the TPB. Literature was preferentially selected for articles from systematic
reviews of relevant randomized controlled trials (RCTs) (Level 1 evidence), RCTs (Level II
evidence) and well designed non-randomized controlled trials (Level III evidence). Melnyk’s
Hierarchy of Evidence (2005) was selected because it is utilized by the Oncology Nursing
Society (ONS).
Scope of Evidence
References related to the efficacy and safety of SC chemotherapy were primarily based
on RCTs. Evidence for the application of the TPB was supported by case controlled and cohort
studies (Level IV). Specific techniques were selected if there were controlled trials and case
controlled or cohort studies. This selection resulted in focusing on site selection, needle size,
whether to change needles before injections (dry needle), whether to purge air from the syringe
or pull air into the syringe (air bubble or air sandwich), needle size, angle of insertion, and
administration time. Recommendations from a review article and expert panel on administering
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SCB (Level VII) were included because there were no studies on SCB administration techniques.
The ensuing guideline was supported with current literature which was primarily relevant to the
administration of SC heparin, insulin, beta-interferon and azacitadine. These data were
applicable to this project in so far as there was a dearth of studies on techniques for
administering SC chemotherapy.
Review of Evidence
Background and the Problem
There was a lack of evidence on how to administer SC chemotherapy. Systematic reviews
of the literature on SC administration of insulin and heparin suggested inconsistency in the
literature to help guide nurses to utilize best evidence for injections. Literature on teaching
patients how to self inject differed and often referenced text books rather than studies. The
techniques supported by studies tended to have consistent findings, except for changing needles
before injections. A common recommendation from systematic reviews, practice reviews, and
clinical studies was the need to determine how nurses actually administer SC injections. These
recommendations supported the need to survey the nurses for this project. The inconsistency in
injection recommendations validated the problem of inconsistent injection techniques.
Systematic Review of the Literature
An extensive database review was completed to identify relevant literature in the field of
nursing, medicine, statistics, and behavior to support the project (Appendix A). Databases
selected for review included Medline, CINAHL and Cochrane Library. Key search terms used
included “subcutaneous bortezomib”, “subcutaneous chemotherapy”, “subcutaneous injection
techniques”, AND “versus intravenous”, “nurs* utilization”, “procedure”, “guidelines,”
“adherence”, “compliance”, “clinical practice skills”, “clinical decisions”, “theory of planned
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behavior”, “survey instrument statistics” and “oncology”. Inclusion criteria included
“randomized trial”, study”, “systematic review”, “review article”, “guideline”, and “practice
article”. Exclusion criteria included “pediatric”, “vaccine”, “editorial”, “case report”. In addition,
a hand search of references in pertinent oncology journals was completed.
Fifty articles from clinical literature were included for this project proposal. The search
resulted in the selection of 30 articles about SC injection techniques (Appendix A).
Predominantly, articles on subcutaneous injection techniques were not oncology specific, and
included two systematic reviews of literature. Additionally, five articles met the most pertinent
criteria of “subcutaneous injection bortezomib”. There were limited articles on subcutaneous
chemotherapy. Articles were included to support the Theory of Planned Behavior and statistical
methods.
Subcutaneous bortezomib. Bortezomib is a proteasome inhibitor indicated for the
treatment of all stages of multiple myeloma (Driscoll et al., 2012). The most frequent adverse
events associated with intravenous bortezomib include peripheral neuropathy (PN). A Phase III
randomized controlled trial (RCT) demonstrated the efficacy of SCB was non-inferior to
intravenous bortezomib. The SC route resulted in fewer grade 3 adverse events and significantly
less PN (38% vs. 53%, p=0.044). Fewer patients stopped treatment due to adverse events on the
subcutaneous arm. At one-year follow up, the data for all end points of efficacy and safety
remained similar across both arms (Arnulf et al., 2012; Moreau et al., 2011; Moreau et al. 2012).
Pharmacokinetic and pharmacodynamics data from the Phase III RCT and a Phase I RCT
confirmed systematic exposure was equivalent for SC versus IV administration. In both the
Phase I and Phase III studies, SC administration sites were in the abdomen and thighs. There
were no differences in pharmacological parameters between these sites (Moreau et al., 2012). A
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different retrospective analysis of 15 Japanese patients experiencing injection site reactions
following SCB reported more incidences of reactions in the thigh than the abdomen (Kaminura
et al., 2012). These data validate safe, effective administration in the abdomen and thigh. The
literature on the Phase I and Phase III studies, and the report from Japan, do not include how the
drug was administered subcutaneously.
Kurtin et al., (2012) described nursing strategies for administering SCB, and indicated the
need to develop SC administration guidelines. The nursing management recommendations
addressed site selection, use of an “air sandwich” technique (p. 408), use of a 4 - 6 mm needle,
pinching to ensure adipose tissue and angle of needle insertion. The summary recommendations
were based on five articles from clinical literature on subcutaneous administration of medications
including one systematic review of literature by Annersten and Willman (2005). S. Kurtin is an
author on two of the five references that describe the use of an air sandwich technique (Kurtin &
Demakos, 2010; Murray et al., 2012). The source of the air sandwich technique was not
referenced in the two articles. Use of the air sandwich technique were also recommended by the
International Myeloma Foundation nurse leadership board at a board meeting (International
Myeloma Foundation [IMF], 2012) The recommendations for SC administration appeared
reasonable, however, appeared based on limited literature review and an expert panel.
Subcutaneous chemotherapy. The Oncology Nursing Society (ONS) and American
Society of Clinical Oncology (ASC0) published standards for administering chemotherapy did
not include guidelines on how to administer SC injections (Jacobson et al., 2011). Anti cancer
agents and oncology supportive care agents that have been administered SC include azacitadine,
trastuzumab, pegfilgastrim, alemtuzumab, dexamethasone, and methotrexate. Randomized
clinical trials that compared standard IV administration to SC reported non-inferior efficacy and
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similar or decreased adverse events between the two routes. The literature reporting
chemotherapy SC clinical trials, review articles, and clinical experiences, did not describe how
the injections were administered (Arthur, Jubb, & Homer, 2002; Du et al., 2005; Ismael et al.,
2012; Stigenbauer et al., 2009; Walker, Lane, & McKenzie, 2010; Waters, Corrigan, Gatesman
& Smith 2012; Wierda et al. 2011). A systematic review of Medline and CINAHL by Annerston
& Willman (2005) found clinical trial literature on SC medications provided pharmacological,
safety and efficacy data but no information on injections techniques or nursing
recommendations. These findings supported this DNP student search results. The lack of
information on how to administer SC anti-cancer agents necessitated incorporating techniques
from other disciplines. The majority of literatures on SC injection techniques were related to
heparin, insulin and instructing patients on self-injection.
Subcutaneous injection techniques. In a systematic review of literature on the scientific
basis for nurses SC administration techniques, Annerston & Willman (2005) found inconsistent
information to formulate clear recommendations based on research, and “no convincing evidence
that a certain technique is better than another just because it has been practiced a long time” (pg.
127). The authors stated this inconsistency prevents nurses from using best evidence for SC
injection techniques and that additional research was needed describing how nurses are
administering SC injections. The subcutaneous administration of bortezomib survey component
of this project described oncology nurses practice in community outpatient clinics.
Needle size and length. Consistent data from several studies indicated appropriate needle
gauge and length are important in SC administration. Small gauge, short needles, appropriate for
the medication formulation, reduces the incidence of pain and injection site reactions. Skin
thickness does not vary significantly in adults, whereas subcutaneous adipose tissue does vary in
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different anatomical sites, between genders, with increased body mass index (BMI), and waist
circumference. In spite of adipose tissue differences, small gauge shorter needles (less than 6
mm) have been shown to effectively deliver SC medications even in obese subjects (Akkus,
Oguz, Uzunlulu, & Kizlgul, 2012; Arendt-Neilsen, Egekvist, & Bjerring, 2006; Birkebaek,
Solvig, Jorgensen, Smedegaard, & Christiansen, 2008; Frid et al., 2010; Gibney, Arce, Byron &
Hirsch, 2010;Gill & Prausnitz, 2007). However, several articles providing instructions and
graphics on how to administer SC injections for nurses and patients recommend 25 gauge or 27
gauge 3/8 to 5/8-inch needles (9.7 to 15mm) (Hunter, 2008; McConnell, 1990; NIH, 2012; Pope,
2002; Rushing, 2004). Small, short needles are not appropriate for delivery of large volumes or
for drug formulations with large particles (Gill & Prausnitz, 2007). Overall, the data suggested
small gauge needles less than 5 mm are appropriate for even obese subjects. Short needles reduce
the need for pinching skin at injection sites and can be injected at 90-degree angles without the
risk of an IM injection. The use of 3/8 or 5/8-inch needles may be based on historical practices.
Dry needle and air bubble technique. Bortezomib is considered an irritant; therefore it
is reasonable to recommend changing the needle after drawing up the medication and prior to
injection to reduce tracking drug during the injection (Kurtin 2012). Changing the needle after
drawing up medication has been recommended to remove particles from the vial and medication
that may adhere to the needle, as well as reduce the risk of dulling the needle from insertion into
a vial (Agac & Gunes, 2011; Giroud & Theoret 2008). One study of two injection techniques
found changing the needle after drawing up the medication, use of an air bubble, and a dry
sponge to prepare the site resulted in smaller areas of bruising (Woodridge & Jackson 1988).
However, one randomized study and one quantitative study did not find a difference in bruising
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when needles were changed before administering the injections (Kingman, 2000; Lamblet et al.,
2011).
Frid et al., (2010) published injection recommendations for diabetic patients based on a
systematic review of literature. The recommendations include priming, or purging, needles to
clear dead space. Two articles providing instructions on how to administer SC injections also
recommend purging the needle prior to injection (Hunter, 2008; NIH, 2012). In contrast to
purging needles, Woodridge and Jackson (1988) described the use of an air bubble technique as
one of four variables that decreased bruising with SC heparin injections, compared to purging the
needle. A two group cross over study of 43 multiple sclerosis patients (11 control, 33
experimental) compared standard SC beta interferon injections using a dry needle to the same
technique using a 0.1 ml air bubble technique. The air bubble modification resulted in a
significant (p = 0.001) decrease in site redness between the groups, as well as in the crossover
group (p=0.002). Patients reported being more satisfied with the air bubble technique and
continued to use it for self-injection six months after the study, suggesting a statistical and
clinical advantage for the technique (Moore et al., 2007).
Site selection, preparation and site rotation. Appropriate sites for SC injections include
the outer aspect of the upper arm, abdomen below the costal margins, above the iliac crest, and at
least 5 cm away from the umbilicus, and the anterior thigh. Site rotation was recommended to
prevent indurations and lypoatrophy (Frid et al. 2010; Girouard & Theoret, 2008; Hunter, 2008;
Kurtin et al. 2012; NIH, 2012; Rushing, 2004). In clinical studies, bortezomib was only
administered in the abdomen and thigh, and sites were rotated with each injection (Moreau,
2011). Millennium Pharmaceuticals has provided a site tracker for nurses to document site
rotations between the abdomen and thigh (velcade.com, 2013). Three articles on how to
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administer SC injections instruct on cleaning the site with alcohol prior to injections (NIH, 2012;
McConnell1990; Rushing, 2004). However, the repeated use of alcohol may cause skin to harden
and is not needed to cleanse the site. The World Health Organization recommends only the use
of soap and water to prepare subcutaneous injection sites, and not alcohol (World Health
Organization [WHO], 2010). A brief review of literature suggested use of alcohol is not
necessary was inconclusive and conflicting (Hunter, 2008; Cocman & Murray, 2010).
Angle of insertion. There was consistency in describing the angle of insertion to ensure
entering subcutaneous tissue rather than risking intramuscular (IM) injections based on needle
size. A study of 388 adult diabetics demonstrated small needles, 4mm - 6 mm in length, inserted
at a 90 degree angle without raising a skin fold will be in the SC tissue more than 98% of the
time. Needles 6 mm to 8 mm inserted at 90 degrees will result in IM injections 5% and 15% of
the time. A 12.7mm (1/2 inch) needle will result in IM injections 45% of the time when inserted
at 90 degree angle and 21% of the time when inserted at 45 degree angle (Gibney, Arce, Bryon,
& Hirsch, 2010). A study of 499 subjects, including 297 healthy controls, suggested the use of
longer needles (> 6mm) without pinching the skin or inserting at a 90-degree angle might result
in an IM injection (Akkus et al., 2012).
Injection duration. Two quasi-experimental studies on SC injection duration
demonstrated 30-second SC injections resulted in statistically significantly less pain and bruising
than 10-second injections (Akpinar & Celbioglu, 2007; Zybak & Khorshid, 2007). The
recommended dose of bortezomib is 1.3 mg/m2. To limit injection volume, the final
concentration for SC bortezomib is 2.5mg/ml compared to 1 mg/ml for IV administration. The
average volume for a SC injection will be just under 1 ml. (VELCADE, 2012). The
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recommended infusion time for IV bortezomib is three to five seconds. There are no
recommendations for SC injection duration (VELCADE, 2012).
Adoption of guidelines and statistics. The American Society of Clinical Oncology and
Oncology Nursing Society (ASCO/ONS) chemotherapy handling and administration guidelines
do not address SC administration techniques (Jacobson et al., 2011). Three descriptive survey
studies of oncology nurses knowledge and implementation of oncology practice guidelines
suggested approximate 80% of respondents were familiar with various clinical guidelines,
however adoption ranged from 40% to 85% (Martin & Larsen, 2003; Nirenberg et al.,
2010;Weingart et al, 2011). Several cohort, descriptive and qualitative studies in the literature
review supported nurses’ knowledge, competence and perceptions of clinical practice guidelines
based on the Theory of Planned Behavior (Cote, Cagnon, Houme, Abdeljelil, & Cagnon, 2012;
Nirenberg, Reame, Cato, & Larson, 2010; O’Boyle, Henley, & Larson, 2001; Phansalker, Weir,
Morris, & Warner, 2008; Zhou, Stoltzfus, Houldin, Marks, & Swan, 2010).
Two articles provided guidance for content analysis of qualitative survey responses
(Bradley, Curry, & Devers, 2007; Hsieh & Shannon, 2005). Two articles provided clarification
on the use of Likert scales for survey instruments (Allen & Seamona, 2007; Norman, 2010). The
authors reinforced the use of non-parametric descriptive statistics for data analysis and reporting
Likert responses. Based on recommendations by Allen & Seamona (2007) the survey developed
for this project forced responses and did not offer a neutral option.
Scope of Evidence
The review of literature supported the need to describe what nurses are doing in order to
develop a guideline on administering SC bortezomib. Variables in injection technique that
decrease injection reactions and were supported by evidence from clinical studies were explored
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and described in the survey and incorporated into the guideline (Agac & Gunes, 2011; Akkus et
al., 2012; Akpinar & Celbioglu, 2007; Frid et al. 2010; Gibney, Arce, Bryon, & Hirsch, 2010;
Girouard & Theoret, 2008; Hunter, 2008; Kurtin et al. 2012; Moore et al., 2007; NIH, 2012;
Rushing, 2004; Woodridge & Jackson 1988; Zybak & Khorshid, 2007). The techniques
included:
•

Injection site selection

•

Needle size and length

•

Use of air bubble

•

Insertion angle

•

Inj ecti on durati on
Project Plan and Evaluation

Market and Risk Analysis
An overview of the market provides evidence for the value proposition of the project
within the clinical setting and health care industry. The oncology health care market is
competitive. Physician owned practices, such as those associated with CCE, compete with
University and Hospital based cancer centers for patients. Competitive advantages, such as
commitment to evidence based care, location convenience, and potentially more personalized
care, are important differentiations (Desch & Blayney, 2006). Championing evidence-based
nursing guidelines demonstrates the networks’ recognition of the importance of nursing for
optimal patient outcomes.
Treatment options for patients with MM have changed. Prior to 2013, bortezomib was the
only proteosome inhibitor on the market and has become the standard of care. A new proteosome
inhibitor is indicated for patients who have relapsed or are refractory to bortezomib and is being
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marketed as having the advantage of less PN (Kortuem & Stewart, 2013). Clinical data
demonstrates SCB results in reduced PN and bortezomib has proven five year survival advantage
not demonstrated by other therapies (Velcade, 2012). Therefore, it is in the interest of patients to
receive SCB as long as there is clinical benefit.
Project Strengths, Weaknesses, Opportunities and Threats (SWOT)
A SWOT analysis provides an overview of elements that may promote or derail a
strategy. The analysis is generally done at the project’s strategic planning stage. The strengths
and weaknesses are internal factors that are readily available and may be strategically addressed.
Opportunities and threats represent external factors that need to be recognized but may not be
controllable. A SWOT analysis was completed during the project planning and is described in
Table 1.

Table 1. SWOT Analysis
STRENGTHS
• Congruent with DNP Capstone purpose
• Investigated nursing practice issue
important to oncology nursing
• Aligned with CCE network mission to
provide evidence based care
• Aligned with Millennium mission to
provide safe, effective treatment for
patient with MM
• Internal stakeholder collaboration
across functions
• CCE headquarters located in CO

WEAKNESS
• Limited time to implement and
complete survey
• Location of clinics across the country
• Investigator developed survey
• Competing priorities for time and
resources
• Number of nurses meeting eligibility
criteria unknown
• Resources to purchase software for
survey
• Medical Director at Millennium lack of
support for nursing projects

THREATS
• IRB approval timelines
• Limited nurse participation
• Nurses competing time and priorities
• Nurses reluctant to recognize need or

OPPORTUNITIES
• Future collaboration with CCE on
outcomes research project
• Guideline may be considered more
broadly and adapted by Millennium
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•

change practice
IMF publication and congress sessions
may influence nurse behavior

•
•

Potential publications
Future collaboration with IMF nurse
leadership council to study SCB

Driving and Restraining Forces
The practice guideline project was designed to help oncology nurses provide evidence
based care in the community setting. The project also helped demonstrate the value of nursing
research projects to Millennium (the company) will be to ensure safe, effective use of drugs in
actual practice settings. It was important to the mission of both organizations to provide safe,
effective treatment and to maximize patient outcomes.
However, there were constraints associated with the project. Complying with legal,
compliance, and regulatory guidelines associated with a product developed and marketed by the
company resulted in numerous consults with the legal department to ensure no conflict of
interests or revelation of proprietary information. Additionally, the project investigator was in an
advanced practice role not associated with a clinical practice site. It was therefore necessary to
identify community oncology clinics willing to participate in the project. One network with
clinics in a metropolitan area in the Mountain region originally agreed to participate, and then
declined in March, 2013. The Cancer Clinics of Excellence network (CCE) was then asked to
and agreed to participate. The CCE headquarters in Colorado, provided convenience and access
for the project investigator to collaborate with the Vice President of Clinical Operations and
Manager of Research. However, the clinics associated with the CCE network are located across
the country, limiting personal contact by the project investigator with the nurses.
Feasibility, Risks, and Unintended Consequences
It was feasible to complete the project within the academic year time frame to ensure
completion by August, 2013 (Appendix C), in spite of CCE not being contacted until March
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2013. Because the clinics are located across the United States (US), CCE was willing to adapt
the survey instrument from a paper and pencil to web based format and to engage the clinic
coordinators to promote the project.
Risks associated with the project included the potential lack of involvement of nurses to
complete the survey instrument. However, in anticipation of this risk, and because the total
number of nurses meeting the inclusion criteria were unknown, a power analysis was not done.
The project investigator was willing to accept the number of responses received after three
weeks. A significant risk to the company would have been the report by a nurse on the survey of
a serious patient adverse event and the inability to identify where the event occurred. Company
employees must report serious adverse events within 24 hours of being made aware of the
occurrence. A risk to CCE was the potential to reveal poor practices among the nurses. However,
the survey was reported in the aggregate, individual nurses and clinic locations could not be
identified.
Project Team
The project team was lead by the DNP student project investigator, and stakeholders at
Millennium and CCE. Team members at the company included the Associate Director of Health
Economics and Outcomes Research (HEOR), one global medical affairs (GMA) Associate
Medical Director, and the Senior Director of Scientific Alliances and Research who is a
doctorally prepared Registered Nurse (RN) with expertise in qualitative research. Two
statisticians agreed to run the data from the survey and the Associate Director of GMA
Publications joined the team after the survey data were known. The CCE team members were the
Vice President of Clinical Operations and the Manager of Research.
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Cost / Benefit Analysis
The direct and indirect costs related to the project were estimated at $23,000 (Appendix
D). Benefits realized from a SC administration guideline include improved nurse patient
relationships due to consistency of techniques used and nurses influence on patient perceptions
about treatment expectations (Schwappach et al., 2010; Weeks et al. 2012). When the SCB
evidence based guideline is adopted by CCE, patient benefit may include decreased injection site
reactions and pain resulting in a willingness to stay on effective treatment with fewer side
effects. The benefit to the company is an understanding of nursing practice in a community
setting that may inform future clinical trial designs. The benefits to clinical practice and patient
outcomes outweigh the cost associated with the project.
Project Objectives
Mission / Vision
The mission and vision of this practice improvement project linked nursing intervention
and patient outcomes and was aligned with the Oncology Nursing Society focus on improving
nurse sensitive patient outcomes (Given & Sherwood, 2005). The mission was to ensure safe,
effective treatment for patients with multiple myeloma who are receiving bortezomib treatment
through development of an administration guideline based on best evidence, clinician experience
and patient preference. The vision was to demonstrate that CCE oncology nurses effectively
deliver high-quality care that impacts nurse sensitive patient outcomes.
Goals / Outcomes
The goal of the project was to describe how oncology nurses at CCE actually administer
SCB and use the best available evidence from the clinical literature to support developing the
guideline. The expected project outcomes included implementation of the guideline at clinics in
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the CCE network. Implementation of the guideline can specifically influence nurse sensitive
outcomes of patients with MM. Outcomes aligned with advanced practice nursing reflect clinical
practice effectiveness (Gawlinski & McCloy, 2009). Oncology nursing patient outcomes aligned
with good SC injection techniques includes:

Table 2 Oncology Nursing Sensitive Patient Outcomes and Measures
OUTCOME

MEASURE

Symptom control and management

Lower incidence of peripheral
neuropathy
Reduced injection site reactions and
pain

Functional Status

Completion of effective treatment
length of therapy

Economics

Reduced clinic time
Reduced cost
Cost effective treatment compared to
other treatment options

Evaluation Plan
Logic Model
Logic models provide a systematic overview of a project in order to demonstrate the
relationship between resources, activities and outcomes expected in the short and long term
(Zaccagnini & White, 2011) Appendix B describes the logic model for this project.
Population
The target population was registered nurses in the CCE network who administered SCB.
All nurses who had ever administered SCB were eligible to participate. There are over 200
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nurses associated with the network, however the numbers who have administered SCB was not
known. Physician assistants who were not nurses, non-registered nurses, and those who
administered IV but not SC bortezomib were excluded from participation. The target population
for the guideline review and implementation was the Vice President of Clinical Operation who
will present the guideline to the network clinics.
Setting
Cancer Clinics of Excellence is a network of physician owned community oncology
clinics in cities through the US. The network’s goal is to “Develop, influence, measure and
support evidence-based best practice cancer care to patients in their own community” (Cancer
Centers of Excellence [CCE], para. 1). The nurses completed the electronic survey on the
network intra-net during clinic hours.
Design and Measurement
This practice improvement project incorporated a project investigator developed
descriptive survey and literature review as evidence for developing the practice guideline. The
Vice President of Clinical Operations and the Manager of Research at CCE were presented with
the project proposal in March, 2013 and agreed to participate. The CCE electronic data base
confirmed SCB was being administered at CCE clinics.
The Manager of Research contacted the local clinic coordinators, who have
administrative positions and were not in supervisory roles to inform them of the project during
conference calls. The project purpose, confidentiality, and investigator contact information were
clarified with the coordinators. The clinic coordinators invited the nurses to participate in the
survey and provided the link to the web survey. The survey was opened on May 20, 2013 and
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remained open for 3 weeks. The project investigator conducted weekly phone calls to remind the
Manager of Research of the project.
The survey was administered once during a three week time period. The project
investigator accessed the aggregated survey results at the end of the open period and analyzed all
responses. The Excel spreadsheet with aggregated results was sent to statisticians at the
company. The qualitative survey responses were logged by the project investigator onto a
separate spreadsheet for analysis. Forty three (43) nurses completed the survey, all survey
questions were answered, and there were no missing data.
The survey results were categorized for the target administration techniques and
compared to the information from the literature. The subjective responses were analyzed for
themes using content analysis to identify potential rationale for responses. The domains of
beliefs from the TPB were cross referenced to evaluate behavior intentions. Where there was less
than 50% agreement on any administration technique, or where there was more than 60%
agreement contrary to the best evidence, questions were flagged as potential techniques that
would require summarizing the evidence to justify changing behavior.
The survey results and a draft guideline were discussed with the Vice President of
Clinical Operations at CCE to ensure commitment to continuing the project. It was determined
that the results were appropriate, and the draft guideline was within the scope of CCE nursing
practice. The final guideline will be presented by the Vice President of Clinical Operations to the
CCE network for implementation at the national meeting of clinicians in September, 2013.
Protection of Human Rights
Institutional Board Approval (IRB) for the project was obtained from New England IRB
and Regis University IRB. The project investigator completed the Collaborative Institutional
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Training Initiative (CITI) certification prior to beginning the project (Appendix F). The CCE
manager of research explained the survey purpose and process to office coordinators at the
clinics where SCB had been administered. The coordinators, in addition to the Manager of
Research, invited oncology nurses to consider participation and explained the purpose and
expected outcome of the survey.
The electronic survey included an introduction explaining the survey and how to contact
the project investigator and academic supervisor (Appendix E). Participation was voluntary as
described on the survey introduction. The introduction emphasized that participation or non
participation would not reflect performance expectations at the clinic. Completion of the survey
constituted the nurses consent to participate.
The web-based survey was confidential and anonymous and the results could not be
assigned to an individual or clinic. The project investigator was given the secure link to the
survey. The aggregated data and spreadsheets are to be maintained in a locked office drawer for
three years by the project investigator in hard copy form.
Instrument Reliability / Validity and Intended Statistics
The project investigator-developed survey, the Subcutaneous Administration of
Bortezomib Survey (SABS) was adapted with permission (A. Niremberg, personal
communication, December 11, 2012, Appendix H), from the Neutropenia Oncology Nurses
Survey ™ (NONS). The NONS instrument was researcher developed to measure the constructs
of the TPB and demonstrated an overall internal consistency, Cronbach alpha = 0.84. (Nirenberg
et al., 2010, p. 767). The Subcutaneous Administration of Bortezomib Survey (SABS)
(Appendix E) content validity was established by five oncology nurses (2 Doctor of Philosophy
(PhD), 1 Nursing Doctorate (ND), 2 Masters of Science in Nursing Advanced Practice
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Registered Nurses (MSN, APRN), one medical oncologist, legal counsel, and three health
economic outcomes research experts. No reliability has been established for the SABS. The
SABS was a 44 item questionnaire, consisting of six demographic questions, 20 questions
addressing practice to identify areas of knowledge and competence; 10 questions addressing
opinions about SC bortezomib to identify behavioral beliefs and eight questions to identify
perceptions of colleague’s beliefs. The survey attributes included four point Likert scales, yes
and no and multiple-choice questions. The Likert scales forced a response in ranking. Many
questions asked for brief explanations for the chosen response.
There were threats to the reliability and validity of the instrument including an author
developed, single use survey instrument. In addition, responses may have been influence by
nurses potentially being more aware of their techniques because of the survey and responded
with what they believed the right answer should be rather than what they actually did in practice.
Non-parametric descriptive statistics, including frequency and percentages were used to
describe the survey results. The project investigator was interested in evaluating the relationship
between question responses such as needle length and angle of insertion, facility privacy,
injection site preference, and consistency of techniques for nurses who believed that practice
guideline were already in place. In these instances Fishers exact test was applied to identify
relationships between these questions. Traditional content analysis was used to summarize the
themes of short answer responses.
The survey described the most prevalent injection techniques used by the nurses for
selecting injection sites, changing needles prior to injecting, selecting needle size, purging or
including air in the syringe, and length of time administering an injection. The common themes
obtained from the content analysis suggested the nurses rational for some administration
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practices (Bradley et al., 2007). This information and the clinical literature were used to develop
a standardized guideline.
Project Findings and Results
The objectives of the project were to 1) develop and administer a survey of oncology
nurses who had administered SCB in the CCE network, 2) develop a practice guideline on the
administration of SCB, and 3) implement the guideline at CCE.
Objective One: The Subcutaneous Administration of Bortezomib Survey Results
Demographics. All respondents were female, approximately half held Bachelor of
Science in Nursing (BSN) as their highest nursing degree, 35% held Associates Degree in
Nursing (ADN) and 12% Diplomas in Nursing. Half were certified by the Oncology Nursing
Society (ONS) as Oncology Certified Nurses (OCN), 30% had been in oncology nursing
between 11-20 years. Table 3 summarizes the demographics. Table 4 validates the inclusion
criteria, representing the number of patients per month to whom respondents administered SCB.

Table 3 Demographics of Oncology Nurses
Highest Nursing Degree
ADN
BSN
MSN
Other (Diploma)
Specialty Certification

Percent
35%
51%
2%
12%
Percent*

Number
15
22
1
5
Number

Not certified

40%

17

OCN

51%

22

Other Certification

12%

5

^M ay not add to 100% due to rounding and multiple certifications
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Table 4 To how many patients do you administer SCB in a month?
Number of patients
1- 5
6-10
More than 10

Percent
46%
33%
21%

Number
20
14
9

Physicians were primarily responsible for ordering bortezomib by the SC route; however,
53% of respondents indicated Nurse Practitioners (NPs) ordered the SC route in their setting.
The majority of nurses (61%) believed they were able to provide some input into decisions
regarding the route of administration.
Administration Techniques - Control Beliefs
Control beliefs reflect the nurse’s confidence and competence in performing the
procedure.
Anatomical site selection. Appropriate site for SC injections include the arm, abdomen
and thigh (National Institutes of Health [NIH], n.d.). In Phase III clinical trials, SCB was only
administered in the abdomen and thigh (Moreau et al., 2011). Nurses reported administering
SCB in the abdomen, arm, and thigh (Table 5). However, 88% indicated their preference is to
administer in the abdomen (Table 6). The reasons for preferring the abdomen included more
adipose tissue, less irritation, easy access, patient preference, and information from the package
insert and literature. Figure 2 compares sites used for administration to those preferred. All
respondents documented the site of injections, although only 23% reported having an anatomical
map in the patient chart to guide site rotations for each injection.
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Table 5 What anatomical site(s) do you use to administer SCB?
Anatomical Site
Abdomen
Thigh
Arm

Yes
98%
19%
54%

No
2%
81%
46%

Table 6 What anatomical site(s) do you prefer to use for SCB?
Anatomical Site
Abdomen
Thigh
Arm

Yes
88%
0%
12%

Figure 2 Comparison of site administration versus site preferences

Figure 2. Comparison of nurse’s actual site selections and site preferences for
administering SCB injections. The abdomen and arm are used most often and preferred.
Facility lay out for chemotherapy administration in community clinics can vary from
private to semi-private. There was an association between administration site preference and
facility layout. Nurses in facilities with more private surroundings preferred the abdominal site
for injections, while those with semi or non-private layouts preferred the arm (p=0.02).
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Needle size and angle of inserting needle. Small gauge, short needles cause less
bruising and injection reactions (Arendt-Neilsen et al., 2006; Birkebaek et al., 2008; Frid et al.,
2010; Gibney et al., 2010). Approximately 40% of the respondents indicated using 25 gauge 5/8inch (15.8 mm) needles, and 56% indicated use of smaller 27 - 30 gauge shorter than 1/ 2-inch
needle (12.7 mm). Of the nurses using the larger 25 gauge 5/8-inch needles, 61% used 45-degree
angle for insertion and 39% used 90-degree angles. For the nurses using the smaller, shorter
needles, 42% used 45-degree angle insertions, while 58% used 90-degree angle insertions
(Figure 3). There was no association between needle size and angle of insertion (p= 0.35). The
literature suggests use of 45-degree angle for needles longer than 6 mm to avoid intramuscular
injections, and 90 degree for shorter needles (Akkus et al., 2012).
Figure 3 Association between needle length and angle of needle insertion for injections

Figure 3. Association between needle size and angle of insertion indicates more than
30% of nurses used 90 degree angles with longer needles. This may result in IM
injections.
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Changing needles and purging or adding air. There is rationale for changing needles
prior to injections, also known as using a dry needle, with drugs that are irritants, such as
bortezomib. Studies have demonstrated no reduction in bruising using a dry needle, while other
studies have revealed reduction in bruising injections (Agac & Gunes, 2011; Kingman, 2000;
Lamblet et al. 2011). Use of a dry needle was most prevalent, with 93% indicating they do
change needles prior to administering SCB.
The literature frequently recommends purging air from the needle prior to injections.
However, clinical studies have demonstrated the use of an air bubble, or air sandwich,
significantly reduced bruising, injection pain, and increased patient acceptance (Moore et al.,
2007; Wooldridge & Jackson, 1988). The survey indicated practices were essentially split, with
49% purging air and 51% pulling air into the syringe. Qualitative responses providing rationale
for the techniques suggested the primary reason for purging air was having been taught to do so,
or habit. The main reasons for using the air bubble was having had attended an in-service or
lecture at a meeting where the technique was explained.
Administration time. Studies have demonstrated that injection times of 30 seconds
result in less bruising than 10 second injections. Recommendations for the time to administer a
SC injection are approximately 10 seconds per milliliter (ml) of drug (Akpinar & Celebioglu,
2008; Chan, 2001;IMF 2012; Kurtin, Knop & Milliron 2012; Moore et al. 2007; Wooldridge &
Jackson, 1988; Zabak & Khorshid 2007). Intravenous bortezomib is administered as a three to
five second push (Velcade 2012). There is no information on how long to administer SCB
injections. Approximately half of the nurses (49%) indicated administering each ml of SCB over
three to five seconds.
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Source of practice standards. Half of the respondents believed the network had a
standard guideline already in place for administering SCB. However, for those who indicated a
guideline was in place, there was no consistency in injection time (p=0.19), use of air bubble
(p=0.31), or needle length and injection angle (p=0.56). Because the literature and textbooks do
not provide clear guidance on SC administration and there is no information in the literature on
administering SCB, the participants were asked to identify the source of their knowledge on SCB
administration (Table 7). Half of respondents indicated their techniques were based on in
services. Five respondents specifically indicated the manufacturer’s sales representatives or
nurse educator provided the in-service information, and one referenced the drug package insert
as the source for information.
Table 7 The technique you use to inject SCB is based on:
Source______________________Yes________________________ No_______________________
My clinical experience
93%
7%
Clinical practice guidelines
72%
28%
Demonstration from
61%
39%
colleagues
Inservice or education seminar 54%
46%
Other
16%
84%
Summary of administration techniques, control beliefs. There were differences and
similarities in injection techniques used for SCB among nurses. The techniques with the greatest
consistency (> 60%) of practice included:
•

Documenting site of inj ection (100%)

•

Rotating injection site within the same anatomical area (67%)

•

Not having an anatomical map in the chart for site rotation (77%)

•

Using alcohol preparation at site (93%)

•

Changing the needle on the syringe (93%)
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•

Pinching a skin fold (81%)

•

Administering in the abdomen (88%)

•

Not administering in the thigh (81%)

•

Injecting in under 10 seconds (84%)

•

Not applying pressure to injection site (63%)
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In general, for the techniques that varied, the technique differences were about half and half.
•

Size of needle 25 gauge 5/8 inch vs. 27-30 gauge ^ inch or smaller (42% vs.
56%)

•

Angle of injection 45 degree vs. 90 degree (51% vs. 49%)

•

Purge needle vs. air bubble (49% vs. 51%)

Considering nurses behavior intentions, there were three evidence based techniques in the
practice guideline that may be problematic for nurses to adopt due to their current practice. First,
the time for an injection should be longer than 10 seconds, and ideally injected over 30 seconds.
Second, needles longer than 1/ 4 inch (6 mm) should be inserted at 45-degree angle to reduce the
risk of an IM injection, even with pinching the skin. Third, the use of an air bubble prevents the
irritating drug from tracking on the needle when inserting or withdrawing the injection, and has
been shown in two studies to cause less bruising and increase patient compliance.
Nurses and patients strongly disliked the thigh as an injection site. Including an
anatomical map in the charts to document abdominal injection sites used may decrease the risk
of abdominal lypohypertophy due to inconsistent site rotation (Australian Diabetic Educators
Association [ADEA], 2011). An anatomical map was incorporated into the practice guideline
(Appendix H).
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Opinions about Bortezomib - Behavior Beliefs
Convenience and patient preference. Overall, nurses believed SCB was more
convenient (Table 8) and took less time than IV bortezomib (Table 9). Reasons for believing
SCB to be more convenient were primarily because it was quicker to administer. Comments
reflected on patient preference and ease for the nurses and patients. Relative to responses about
the time to administer, nurses primarily commented on the difference in time to start an IV,
running pre medications, and hydration and gathering the supplies for an IV. Some indicated the
actual injection time is the same as the IV push, which is congruent with the information that
many nurses are administering the SC injection over three to five seconds. Time conveniences
for the patient included not having to wait for a treatment chair or IV fluids. One respondent
believed patients to be more compliant with the SC route.
Nurses were divided as to whether privacy concerns influenced site selection. However,
the results suggest an association between site selection and facility privacy. Several commented
that many patients, especially women, were less willing to expose their abdomen and more
privacy was needed and provided for abdominal injections.
The majority of nurses (86%) believed patients prefer SCB to IVB. The primary reason
for patient preference stated was that it took less time and they did not have to get an IV stick.
Five nurses commented that some patients have experienced injection site reactions described as
“skin irritation, sensitivity reaction at site of administration, red welts, skin sites get quite sore
and site reactions”. Five also commented patient preference is due to decreased neuropathy with
SCB.
Most nurses (72%) believed patients preferred the abdomen, while 28% believed patients
preferred the arm for SC injections. The primary reason for patient preference was less pain and
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redness with abdominal injections. Other reasons for preferring the abdomen were ease of
access, modesty, and not having to redress.
Table 8 Overall; is the SC route more or less convenient for nurses to administer than the IV
route?
Convenience
Subcutaneous
Subcutaneous
Subcutaneous
Subcutaneous

much more convenient
somewhat more convenient
somewhat less convenient
much less convenient

Percent
84%
14%
0%
2%

Table 9 Overall; is there a difference in the time it takes to administer SCB versus IVB?
Time
Much less time for SC
Somewhat less time for SC
Somewhat more time for SC
Much more time for SC

Percent
67%
28%
5%
0%

Summary of opinions and behavior beliefs
Nurses believed the SC route to be more convenient and that patients prefer SCB to IV.
These beliefs will support Duffy’s Quality Caring Model when presenting a guideline based on
their own practice and clinical evidence. Nurses are responsible for using evidence in practice
and applying attitudes and behaviors of caring. Improvements in health outcomes are possible
when caring relationships are integrated into nursing practice. The Theory of Planned Behavior
(Azjen, 2007) suggests behavior beliefs will predict willingness to act. Rationale for the practice
guideline will include evidence from the literature about the convenience and cost effectiveness
of SC chemotherapy (Du et al.2005) as well as information from the SABS on nurses and
patients beliefs about the convenience of SCB.
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Perceptions of Others, Subjective Beliefs
There was general agreement that all nurses used similar techniques for administering
SCB (Table 10). The belief in consistency was due to incorporating information from attendance
at in-services or standardized teaching in the clinic. However, several commented that there were
different techniques being used and being observed, patients had commented on differences and
indicated having favorite nurses for injections, and nurses had different training or different
experiences. Respondents agreed that consistency was important to patients for continuity of
care, safety and to reassure the patients.
Table 10 All nurses in this clinic use the same technique to administer SCB
Same technique____________________________ Percent
Completely agree
39%
Somewhat agree
56%
Somewhat disagree
5%
Disagree completely
0%
Adherence to practice guidelines
Participating nurses agreed that practice guidelines are important for consistency and
quality care, and if the techniques being used differed from a practice guideline, they would be
willing to change. Half of the respondents indicated there was a standard guideline in their clinic
for administering SCB, 20% indicated there was not a guideline and approximately 30% were
unsure. For those who believed there was a standard guideline, there was no consistency in the
time to administer an injection (p=0.19), use of the air bubble (p=0.31) or angle of insertion
(p=0.56).These findings are supported by clinical literature that indicates although guidelines
may be in place, clinician (nurses and physicians) adherence and knowledge of the guidelines is
inconsistent even when the clinicians agree about the importance of following guidelines (Binner
et al., 2011; Cote et al., 2012; Martin & Larsen, 2003; Nirenberg et al., 2010; O’Boyle et al.,
2001; Squires et al., 2007).
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Objective Two: Results for Evidence Based Practice - Development of the Subcutaneous
Administration of Bortezomib Practice Guideline
A comprehensive clinical literature review supported the lack of standard SC
administration techniques, the need to describe how nurses are administering subcutaneous
injections and to develop evidence based practice guidelines in order to improve patient
outcomes by potentially reducing injection site reactions and injection site pain. Reducing the
adverse events associated with inconsistent injection techniques may result in patients complying
with treatment and completing effective therapy.
The Capstone Project process identified the different techniques oncology nurses in a
network of cancer clinics used to administer SC bortezomib and lack of standard practice
guidelines for the administration of subcutaneous chemotherapy. The practice guideline
developed was based on evidence from the actual practice of 43 oncology nurses who
administered SC bortezomib to patients in a network of community oncology clinics and
supported with evidence from the clinical literature. The Subcutaneous Administration of
Bortezomib Practice Guideline included descriptions of potential patient benefit, levels of
evidence and graphics for specific techniques (Appendix H) Permission was granted for use of
the graphics (Appendix G).
The specific techniques in the guideline recommendations included:
•

Anatomical site rotation and use of an anatomical map

•

Appropriate method of skin pinch to ensure access into adipose tissue

•

Use of 45 degree angle with needles that are longer than 6 mm (1/ 4 inch) to avoid
risk of intramuscular injections

•

Use of dry needle
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•

Use of air bubble

•

Injection duration of 10 to 30 seconds
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Objective Three: Implementation of the Practice Guideline
The Subcutaneous Administration of Bortezomib Practice Guideline was presented to the
Vice President of Clinical Operations for review and approval. The Vice President of Clinical
Operations will present the guideline for implementation at the September 2013 CCE national
meeting. The project investigator will follow up with the Vice President in October, 2013.
According to the constructs of the Theory of Planned Behavior (Azjen, 2012),
incorporating information on what the nurses were actually doing, what they believed about SC
bortezomib and their perceptions of what patients and colleagues believed about SC bortezomib,
implementation of the guideline is likely to occur. Adoption of the practice guideline at CCE is
possible with appropriate staff education.
Joan Duffy’s Quality Caring Model can be the framework for educating CCE nurses
about the Subcutaneous Administration of Bortezomib Practice Guideline. The model contends
that through self-evaluation of practice, collaborative relationships, and adoption of evidencebased practice, nurses can improve patient caring and outcomes.
Limitations, Recommendations and Implications for Practice
Limitations
There are several limitations to this project. First, the project investigator developed the
SABS survey instrument based on adaptation of the Neutropenia Oncology Nurse Survey™.
Although the SABS was reviewed for content validity, there is no established and validity for
this instrument. In addition there is no instrument reliability. Second, the survey results only
reflect one community oncology network. Third, the number of respondents was small. Finally,
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the survey was administered after some of the surveyed nurses had attended education sessions
on SCB injections which may have influences their responses. The findings cannot be
generalized to other community oncology networks, independent community practices, or
academic cancer centers.
Recommendations
The purpose of this project was to develop and implement a practice guideline on the
administration of SCB for a community oncology network. The project was in alignment with
the clinical literature assertions that nurses use different techniques for SC injections. Different
techniques are recommended in the literature and textbooks. Project surveyed nurses agreed
guidelines result in consistency of care that is important to patients. It would be reasonable to
recommend oncology nurses assess how nurses are administering SC injections in order to better
understand current practice.
The results of this project suggested potential opportunities for future nursing research.
There is no evidence that adopting a practice guideline will result in fewer injections site
reactions. The incidence of SCB injection site reactions in actual practice is unknown. A clinical
study comparing the incidence of injection site reactions and patient reported outcomes when
following the guideline injection technique is needed.
A weakness associated with new SC drugs is the lack of information drug manufacturers
provide on how to administer the SC injections (Annerson & Williams, 2005). Drug
manufacturers could improve data reports by including evidence based SC administration
techniques in the drug study designs. Including information from clinical trials on how to safely
administer SC injections, along with the safety and efficacy data, may mitigate the risk of
injection site adverse events when drugs are more widely used after approval. This project
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exposed members of the Millennium project team to the importance of considering nursing
interventions in study design to improve patient outcomes.
The manufacturer of bortezomib, Millennium, the Takeda Oncology Company, was
willing to sponsor this project in the interest of identifying what nurses are actually doing when
administering SC bortezomib injections. Millennium may not be able to recommend the
guideline that was developed for this project. Cancer Clinics of Excellence reviewed the
guideline and agreed to its implementation. A comprehensive training plan that engages
Advanced Practice Nurse Practitioners (APRNs) as champions throughout the network may
improve the likelihood of widespread adoption. Nurse Practitioners currently have responsibility
for ordering SCB in some of the network clinics. Championing and promoting evidence based
guidelines can provide APRNs continuity in advanced practice roles within the CCE
organization. The APRNs can influence the outcomes that are most meaningful to patients by
modeling the importance of consistent caring practice to patients and supporting professional
collaboration with evidence based practice (Gawlinski & McCloy, 2009). Adopting the guideline
will contribute to nursing practice by demonstrating evidence based care impacts nurse sensitive
patient outcomes.
Summary
Essential to the Doctor of Nursing Practice (DNP) role is improving patient outcomes and
the overall quality of healthcare organizations (Zaccagnini & White, 2011). The Subcutaneous
Administration of Bortezomib Guideline Capstone Project endeavored to advance oncologynursing practice in a network of community oncology clinics in order to improve patient
outcomes. Additionally, the project introduced the value proposition of nursing outcomes
projects in a global oncology pharmaceutical company medical affairs organization. The project
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addressed the first three essentials of a DNP education (American Association of Colleges of
Nursing [AACN], 2006).
First, the scientific underpinnings of practice were met by utilizing evidence from the
clinical literature and actual practice. Second, the project investigator demonstrated
organizational and system leadership for quality improvement and system thinking within in a
network of oncology clinics committed to evidence based practice and a global pharmaceutical
company committed to developing effective oncology therapeutics. Third, clinical scholarship
and analytical methods for evidence based practice were achieved by critically collecting and
analyzing data to develop a guideline consistent with the principles of evidence based practice.
The Subcutaneous Administration of Bortezomib Capstone Project met the criteria of
investigating a practice issues and developing outcomes solutions to improve clinical practice for
the benefit of a population.
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from experienced
nurses. Not
generalizable due to
he expertise of the
respondents may not
reflect general
practice

Funding
Source
Comments

Not indicated

SEER data highly reliable
and valid to monitor cancer
control & prevention.
Medicate covers IV
chemotherapy inpatient and
outpatient. Limitations:
cannot be generalized
beyond women >65 y/o
with breast cancer who are
not covered by HMOs or
fully covered by Medicare
A&B. Codes could be
misclassified, dose of
chemotherapy not known
that may have impact on
adverse events
NCI

Roche Pharmaceutical

Applicable to PICO
due to design of
questionnaire and
evidence that
oncology nurses

Risk of adverse events
lowest with SC vs IV
administration. Only 1% of
admin is SC, possible lack
of knowledge due to less

Ph III non-inferiority of
SC MOAB.
Administration technique
not clearly described. 5
min SC administration

RCT with PK/PD
evidence. Limitations,
applicable only in neo
adjuvant setting. SC dose
mixed with 10,000U
RHuPH enzyme to
improve SC absorption. 4
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prepare own
chemotherapy, 87%
education on chemo
admin, 85% policies
in place. Suggests
capstone population
may be preparing
chemo, may not
have been educated
and not have, or not
realize SOP for SC
admin

Article Title

Author, year,
Journal

frequent mode. Substantial
geographic variations
"important public health
implications because if the
modes of administration are
associated with subsequent
outcomes it may be possible
to take steps to prevent
negative outcomes by
controlling for the preferred
mode/route of
chemotherapy
administration" (p 922).
Application to PICO - may
support lack of SOP for SC
administration and
opportunity for teaching and
change in practice.

4
Explaining the role
of organizational
policies and
procedures in
promoting research
utilization in
registered nurses.

5
Patients’
expectations about
effects of
chemotherapy for
advanced cancer

Squires, J.E.,
Moralejo, D.,
LeFort, S.M. (2007
June 5)

Weeks, J.C.,
Catalano, P.J.,
Finkelman, M.D.,
Mack, J.W.,
Keating, N.L.,
Schrag, D. (2012
October 25) New

Implementation
Science 2(17)
doi:10.1186/17485908-2-17

Data Base & Key

BioMed Central,

would be difficult to
administer and would
require extensive nursing
teaching. Butterfly used
for SC administration
and sites were moved due
to volume (Personal
communication T. Caver
October 5, 2012).
Application to PICO
supports literature does
not describe how to
administer SC anti cancer
agents

6'
Oncology nurses’
use of national
comprehensive
cancer network
clinical practice
guidelines for
chemotherapyinduced and febrile
neutropenia
Nirenberg, A.,
Reame, N.K., Cato,
K.D., Larson, E.L.
(2010 November)

Oncology Nursing
Forum. 37(6) 765

England Journal o f
Medicine. 367(17)

772 doi:
10.1188/10.ONF.76
5-773

1616-1625 doi:
10.1056/NEJMoa.1
204-410
Retrieved from
nejm.org
NEJM.org

ONS.org/publicatio
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Words

Open Access.
Perceptions nurses
utilization
procedures

Patient perceptions
chemotherapy

Research Design

Cross sectional
survey

Descriptive survey
interview

Level of Evidence
Study Aim/Purpose

VI
Identify factors
influencing
registered nurses to
use and follow
organizational
policies and
procedures

Methods/ Study
Appraisal

Staff and agency
RNS in one eastern
Canadian Provence,
Newfoundland and
Labrador. Medical,
surgical and critical
nurses. 464 surveys
mailed, 58%
response rate N=
248 .
Staff Nurse
Questionnaire
(SNQ) 96 items
revised from Nurses
Practice
questionnaire
(NPQ), tested for
reliability on 12
nurses. Descriptive
statistics

VI
Characterize the
expectations of
patients with
advanced colorectal
and lung cancer
about the
effectiveness of
chemotherapy and
expectations for
cure and to identify
the clinical,
socioedemographic
and health system
factors associated
with expectations of
cure (p 1617)
Patients (or
surrogate if pt too
ill) from patients in
national Cancer
Care Outcomes
Reearch And
Surveillance
(CanCORS) study
with advanced
colorectal or lung
cancer. Interviewed
4 - 7 months after
diagnosis by
telephone interview
software. Questions
adapted from Los
Angeles W omen’s
Health Study to
elicit “how likely
did you think..”

ns Evidence
practice, adherence,
procedures,
guidelines,
perceived
competence
Cross-sectional
survey
VI
Describe oncology
nurses use of
guidelines in
practice

Neutropenia
Oncology Nurses’
Survey Web based
random sample of
US RNs members
of ONS. Survey
available online for
two weeks through
ONSEdge. Survey
measured constructs
of Theory of
planned behavior:
subjective norms,
attitudes, perceived
behavioral control,
perceived barriers
to use of NCCN
guidelines.
Psychometric
properties for
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summarized data.
Cross tabulations
and chi square for
dichotomous data,
stepwise
multivariate
analysis for factors
predicting use of
P&P

Primary
Outcomes/Measures
/Results

Table 2 Frequency
of use of resources
for practice. In the
frequently/always
use category: 81.9%
P&P, 81.1%
personal
experience; 58.5%
fellow nurses;
32.6% Always done
that way

Author
Conclusions/
Implications of Key
Findings

Multivariate
regression analysis
identified three
significant
predictors of being
a user versus non
user of RBP
overall: awareness,
awareness by
regular use, and
persuasion. Six
significant

likert like responses
of very, somewhat,
a little, not at all
likely or don’t
know.
Questions on
patient / physician
communication,
QoL, patient role in
decision making .
Four level
responses analyzed
with non-parametric
test for trends.
1193 of 1274
patients (93%)
opted for
chemotherapy. 69%
with lung cancer
and 81% with
colorectal believed
chemo was very
likely to cure their
cancer. Variables
associated with
expectations were
colorectal cancer
and nonwhite race.
Patients from
integrated health
care networks were
less likely to
provide inaccurate
responses.
Rate of inaccurate
responses higher
than from previous
small studies.
“paradoxically,
patients who
reported higher
scores for physician
communication
were also at higher
risk for inaccurate
expectations”

instrument internal
consistency,
Cronbach alpha =
0.84.
Descriptive
statistics compared
to ONS
membership.
Bivariate analysis
of identified
variables,

Guidelines were
more likely to be
used when expected
by physicians and
nurse colleagues.
Oncology certified
nurses perceived
fewer barriers to
use of guidelines

Although 80%
reported using
guidelines for CIN
and FN, only 56%
reported it was their
own decision. On
line survey of ONS
members feasible.
Provided insights
into future member
surveys.
Need to develop
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predictors of being
a consistent versus
less consistent user
of RBP overall
were also identified:
perception of P&P
existence, unit,
nursing experience,
personal experience
as a source of
practice knowledge,
number of existing
research-based
P&Ps, and lack of
time as a barrier to
consulting P&P
manuals.

(p1620) Patients
ability to make
informed decisions
will be impaired if
they don’t
understand
treatment is not
curative. This
suggests a
significant obstacle
to end of life
planning.
“Physicians have
some ability to
influence patients’
understanding.

standard nursing
protocols. Most
respondents from
community settings
where oncology
care is shifting.

Strengths/limitation
s

Multicentered
survey with >200
respondents.248
respondents may
not have been
enough to identify
differences in
variables. Nurses
alerted to existence
of P&P being
important.
Questionnaire not
validated. Not
generalizable
outside of Canadian
provences or
community practice

309 oncology
nurses providing
direct patient care,
self selected from
ONS membership.
Limitations: Only
9% response rate.
Web based format
open only to
computer users.
Survey conducted
one month before
ONS Congress may
have respondents
with more
professional
interest. Self report
may result in
overestimation

Source of Funding
Comments

Not indicated
Factors influencing
use of P&P include
perceptions of
whether or not
procedure exists,

Very large sample
size, population
based and scope of
sociodemographic
data collected.
Limitations: due to
timing of interview
after diagnosis,
unable to comment
on beliefs of those
who died shortly
after receiving
chemotherapy.
Single survey does
not identify if
beliefs changed
over time.
Interviewers may
not have been
skilled enough to
delve more deeply
into responses
NCI
Support of PICO clinicians can
influence patient
perceptions about
treatment. Suggests

Not indicated
Based on Theory of
Planned Behavior
supported basis for
survey development
and assessing
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Article Title

Author, year,
Journal

Data Base & Key
Words

personal experience
and peer
experience. This
information may
support hypothesis
that whether or not
SC procedure in
place, nurses may
rely on past
experience or other
nurses for SC
chemo
administration.

nurses can influence
preferences about
SC. Supports
importance of
clinician
communication of
actual data in ways
patient can
understand and
apply to own
situation.

outcomes.
Provides framework
for project survey:
• Attitudes
• Subjective
norms:
perceptions
about
colleagues
• Perceived
self
competence
• Perceived
barriers
• Reported
use

7
Updated survival
analysis of a
randomized phase
III study of
subcutaneous
versus intravenous
bortezomib in
patients with
relapsed multiple
myeloma
Arnulf, B.,
Pylpenko, H.,
Groscki, S.,
Karamanesht, L.,
Lelu, X., Van de
Velde,
H.,...Moreau, P.
(2012, June 11).

8
US cancer center
implementation of
ASCO/Oncology
Nursing Society
chemotherapy
administration
safety standards

9
From simplicity to
complexity:
developing a model
of practical skill
performance in
nursing

Weingart, S,N, Li,
J.W., Zhu, J.,
Morway, L., Stuver,
S.O., Shulman,
L.N., & Hassett
M.J. (2011 Dec 6)

Bjork, I T.,
Kirkevold, M.,
(2000) Journal of

MedLine
Subcutaneous
bortezomib

Clinical Nursing.
9. 620-631

Journal of
Oncology Practice.
Retrieved from
joppubs.org as
doi :10.1200/J OP.20
11.000379
ASCO Publications
Adherence
guidelines,
chemotherapy
administration

CINHAL
Clinical nursing
skill, practice skill,
skill performance
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Research Design
Level of Evidence
Study Aim/Purpose

II
Update data from
Phase III non
inferiority study

Methods/ Study
Appraisal

Phase III RCT
Non-inferiority
design
Updated time to
event endpoints
Response rates and
adverse events
Comparing IV and
SC administration
2:1 randomization

Primary
Outcomes/Measures
/Results

Best response after
10 cycles
bortezomib +
dexamethasone
IV vs. SC
52% each arm

Written survey
VI
Determine the
implementation of
chemotherapy
administration
standards in NCI
designated cancer
centers
Written survey
using exact, or near
exact phrasing of
standards. Degree
of implementation
responses on 4 scale
likert or binary
yes/no scale.
Defined standard as
fully implemented
if more than 90% of
responses were
mostly positive,
partially
implemented if 50
90% mostly
positive and not
implemented if
<50% positive.
Internal consistency
within domains
Cronbachs alpha
>0.7 for six of 8
domains. 44 of 55
eligible centers
responded.

6 standards were
fully implemented
in at least 80% of
the centers. The
standards with
lowest

observational
VI
New model of
nursing practical
skill performance

Videotaping 4 new
nurses 3 times over
3-5 months during
skills of wound
dressing change and
post=-op
ambulation. Nurses
and patients were
interviewed. Nurses
on intentions and
appraisals before
and after and
patients on
expectations and
experiences.
Models of skills
were created with
coding scheme for
action and set of
performance
categories
developed:
substance and
sequence, accuracy,
fluency, integration
and caring conduct.
Empirical data were
compared with the
components to
check model
validity
Practical skills are
highly complex and
what seems like
simple skills are
integrated and
comprehensive.

60

Subcutaneous Bortezomib
23% / 22% CR
9.7 mo /9.6mo TTP
9.3 mo/8.6 mo PFS
76% /78% 1 yr OS
PN
53% / 38%
subsequent therapy
57% / 53%

Author
Conclusions/
Implications of Key
Findings

Confirms SC as
effective as IV with
improved safety
profile

implementation
were providing
chemo education
materials before
administering
chemo, providing
oral chemo-specific
materials, written
guidance about
regime specific lab
testing intervals and
chart
documentation
during chemo
planning. Only 4
centers had fully
implemented all 31
standards
Slow adoption may
be due to
complexity of
standards and the
infrastructure
required to support.
Even if electronic
systems were to
become available
through HER, it
would require
significant work
flow changes and
staffing. Lack of
detailed written
patient education
and support may
“account for the
problems with safe
handling, adherence
and reporting
noted” in recent
literature.
Variability in NCI
center practice
suggests even more
variability in other
settings.

Relying on
procedure
knowledge is
inadequate because
technical skills are
complex actions.
Cannot just address
motor component of
skills, must
integrate knowledge
and caring
considerations
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Strengths/limitation
s

Observational study
may altered natural
practice. Observer
bias.

Source of Funding

Packaging concepts
Assoc. LLC

Comments

Nurses adherence to
practice guidelines
may not be
congruent with
perceptions of
practice. Support
PICO hypothesis of
perceptions versus
practice of SC
administration

There is variability
in adherence to the
safety standards,
with opportunities
for improvement.
“ Social desirability
bias may have led
respondents to
report more
favorable adherence
“(p 5). Centers are
complex and
multiple specialties
are involved in
chemotherapy
process, though one
person facilitated
the survey, usually
the clinical
pharmacist.
Nonresponse bias
from the 11 centers
that did not respond
may differ.
Authors Weingart,
S.N & Shulman,
L.N
Supports project
hypothesis of
variable adherence
to standard
procedures even
when standards
exist.

Small study,
theoretical nature
designed to develop
a model.

Not indicated

Cannot assume
because a procedure
is in place nurses
are able to perform
what may seem to
be simple nursing
skills. Nursing
education focus on
theory and
professionalism has
resulted in less time
on clinical skills.
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Article Title

Author, year,
Journal

Data Base & Key
Words

10
Revisions to the
2009 ASCO/ONS
standards for safe
chemotherapy
administration:
expanding the scope
to include inpatient
settings

Jacobson, J.O.,
Polovich, M.,
Gilmore, T.R.,
Schulmeister, L.,
Esper, P., LeFebvre,
f B., & Neuss, M.N.
(2011) Journal o f
Oncology Practice .
Retrieved from
http://jop.ascopubs.
org/ content/ 8/1/2.fu
ll?sid=9c7e1e88b12a-4cc1-8641e78ba3e5b3e2
ASCO publications
Chemotherapy
standards

Research Design

Practice guideline

Level of Evidence
Study Aim/Purpose

VII
Revision of
standards for safe
chemotherapy
administration

11
Pharmakokinetics,
pharmacodynamics
and covariate
analysis of
subcutaneous
versus intravenous
administration of
bortezomib in
patients with
relapsed multiple
myeloma.
Moreau, P.,
Karamanesht, I.I.,
Dominkova, N.,
Kyselyova, M.,
Vilchevska, K.V.,
Doronin, V.A.,
Schmidt, A.,
...Facon, T. (2012
Sept 25) Published
online Clin

12
Chemotherapyinduced peripheral
neuropathy:
assessment of
oncology nurses'
knowledge and
practice.

Binner, M., Ross,
D., Browner, I.
(2011 July)

Oncology Nursing
Forum 38(4)448454
doi:10.1188/11.ON
F.448-454

Pharmacokinet.
DOI
10.1007/s40262012-0010-0
Medline
subcutaneous
bortezomib,
pharmacokinetics
Phase III open label
RCT AND
Randomized Ph 1
II
present a
comprehensive
analysis of the
pharmacokinetics
and
pharmacodynamics
of subcutaneous
versus intravenous
bortezomib, and to
evaluate the impact
of the subcutaneous
administration site,

ONS.org oncology
nurs* knowledge,
practice, perception
cross sectional,
descriptive
VI
explore oncology
nurses knowledge
and practice
behavior of
assessing for
chemotherapy
induced PN
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Methods/ Study
Appraisal

40 stakeholders,
including medical
oncologists,
oncology nurses,
oncology
pharmacists, social
workers, practice
administrators, and
patient advocates,
as well as
representatives
from American
Cancer Society,
Association of
Community Cancer
Centers, National
Quality Forum,
National Coalition
for Cancer
Survivorship, The
Joint Commission,
and Institute for
Safe Medication
Practices met for a
single day and,
using a structured
process, drafted 64
chemotherapy
administration
safety standards.
The draft standards
were subsequently
presented to the full
group of
participants for
comment and
discussion, and

subcutaneous
injection
concentration and
demographic
characteristics on
bortezo- mib
pharmacokinetics
and
pharmacodynamics.
age >18 <65
relapsed or
refractory MM 1 - 3
prior therapies. In
Ph III 32 of 222
patients had PK/PD
(18 SC & 14
IV)from Ph I 10
patients each group.
Power ratio and
90% CI point
estimates AUC
mean. Equivalence
defined as 90% CI
falling between 85
125%. Regression
covariates
demographics
PK /PD collected
day 11 of cycle 1
immediately or 30
minutes pre-dose
and 2, 5, 15 and 30
minutes post dose,
and 1, 2, 4, 6, 10,
24, 36 and 72 hours
post dose
comparing SC vs
IV PK/PD.
Pharmacokinetic
parameters included
the area under the
plasma
concentration-time
curve (AUC) from
time zero to the last
quantifiable time-

convenience sample
39 oncology nurses
in two hospital
based outpatient
chemotherapy
infusion clinics
Author developed
questionnaire "The
Chemotherapy
Induced Peripheral
Neuropathy:
Assessment o f
Oncology Nurses
Knowledge and
Practice
Questionnaire" 16
knowledge and 16
practice items, 9
demographic items.
Content validity
0.95 and reliability
Cornbach alpha
0.85. Descrriptive
statistics
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Primary
Outcomes/Measures
/Results

assessed for
redundancy and
gaps. Participants
voted on the draft
standards within 1
week of the
workshop, and the
SG used the voting
results to clarify
and edit the
standards, reducing
their number to
35.(p

point (AUClast),
maximum (peak)
plasma drug
concentration
(Cmax), and time to
Cmax (tmax).
Pharmacodynamic
parameters were
calculated by
analysis of data on
the percentage
inhibition of the
20S proteasome in
blood over time,
which was
determined based
on the change in
pro- teasome
activity from
baseline (pre-dose)
to subsequent time
points.
Pharmacodynamic
parameters included
area under the
effect-time curve
from time zero to
72 h (AUEC72),
maximum
percentage 20S
proteasome inhibi
tion [maximum
effect (Emax)] and
time to Emax.

Primary change was
to include inpatient
setting

Table 1. systemic
exposure was
equivalent to
subcutaneous
versus intravenous
administration,
mean AUClast was
155 versus 151
ngDh/mL, subcuta
neous injection
concentration had

75% rated
assessment skills as
poor or fair, only
15% had prior PN
assessment
teaching, barriers
included lack of
knowledge, time
and inadequate
tools, 33% routinely
screened for PN
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no appreciable
effect on
pharmacokinetic
parameters, blood
20S proteasome
inhibition were also
similar with
subcutaneous
versus intravenous
bortezomib. the site
at which the
subcutaneous
injection was
administered and
the concentration o f
the injected solution
(2.5 or 1 mg/mL)
did not appear to
affect the
pharmacokinetic
and
pharmacodynamics
parameters o f
bortezomib
following
subcutaneous
injection,
demonstrat- ing the
feasibility o f using
a higher
subcutaneous
injection
concentration (2.5
mg/mL) in order to
minimize the vol
ume injected per
dose o f bortezomib.
In both studies,
subcutaneous
injection sites were
the thighs and the
abdomen (but not
the arms); the
absence o f any
apparent differences
in pharmacological
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parameters between
these sites indicates
that both represent
equally feasible
sites for the
subcutaneous
administration o f
bortezomib.
Addition- ally,
demographic
covariates did not
appear to have an
impact on the
systemic exposure
with subcutaneous
bort- ezomib, when
dosed on the basis
of BSA, suggesting
the feasibility o f
this route o f
administration
regardless o f a
patient’s age or
bodyweight.
Author
Conclusions/
Implications o f Key
Findings

Standards, 12, 13,
14 Drug prep.
12. A second person
(a practitioner or
other personnel
approved by the
practice/institution
to prepare or
administer
chemotherapy)
independently
verifies each order
for chemotherapy
before preparation,
including
confirming:
A. Two patient
identifiers
B. Drug names

SC administration
non inferior to IV.
Efficacy related to
systemic exposure,
not Cmax. SC
resulted in less
grade 3 adverse
events, most
importantly,
significantly less
Peripheral
Neuropathy

Lack o f confidence,
knowledge and
assessment skills
prevent routine
assessment. Need
for clinical
guidelines on PN
assessment and
more assessment
education
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C. Drug dose
D. Drug
volume
E. Rate of
administrati
on
F. Route of
administrati
on
G. The
calculation
for dosing
(including
the variables
used in this
calculation)
H. Treatment
cycle and
day o f cycle
13. Chemotherapy
drugs are labeled
immediately upon
preparation,
including, at
minimum:
A. Patient’s full
name and a
second
patient
identifier
(e.g.,
medical
record
number,
DOB)
B. Full generic
drug name
C. Drug
administrati
on route
D. Total dose
to be given
E. Total
volume
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required to
administer
this dosage
F. Date o f
administrati
on
G. Date and
time o f
preparation
H. Date and
time o f
expiration
when not for
immediate
use*
*Immediate use
must be defined by
institutional policy,
state, and federal
regulations (e.g. use
within 2 hours).
Practices/institution
s are not expected
to be in full
compliance with
this standard i f they
currently have
electronic systems
that are unable to
meet these labeling
requirements.
Appropriate
changes should be
implemented as
soon as possible to
ensure that
electronic labels
integrate all o f these
elements.
14.
Practices/institution
s that administer
intrathecal
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medication
maintain policies
specifying that
intrathecal
medication will:
A. Not be
prepared
during
preparation
of any other
agents.
B. Be stored,
once
prepared, in
an isolated
container or
location
with a
uniquely
identifiable
intrathecal
medication
label.
C. Be delivered
to the
patient only
with other
medication
intended for
administrati
on into the
CNS.
Standard 18-20
Administration
18. Before
chemotherapy
administration:
Confirm with the
patient his/her
planned treatment
prior to each cycle;

Subcutaneous Bortezomib
At least two
practitioners or
personnel approved
by the
practice/institution
to prepare or
administer
chemotherapy,
verify the accuracy
of:
A. Drug name
B. Drug dose
C. Drug
volume
D. Rate of
administrati
on
E. Route of
administrati
on
F. Expiration
dates/times;
if
applicable:
[expiration
date/time is
not required
if for
immediate
use*]
G. Appearance
and physical
integrity of
the drugs
H. Document
to indicate
verification
was done
and;
I. At least two
individuals,
in the
presence of
patient,
______ verify the
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patient
identificatio
n using at
least two
identifiers
(e.g.,
medical
record
number,
DOB)
* Immediate use
must be defined by
institutional policy,
state, and federal
regulations (e.g. use
within 2 hours).
19. Extravasation
management
procedures are
defined and align
with current
literature and
guidelines; antidote
order sets and
antidotes are
accessible.
20. A licensed
independent
practitioner is on
site and
immediately
available during all
chemotherapy
administration.
***In organizations
or home care
settings where
chemotherapy may
be administered
24/7,
patients/caregivers
should be explicitly
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educated in
procedures for
unplanned events
and circumstances.

Strengths/limitation
s

Source of Funding

ASCO/ONS

Comments

Provides standards
for project

PK/PD data from
two randomized
studies confirms
non inferiority of
SC vs IV
administration.
Small number of
patients with grade
3 adverse events
included in PK/PD
evaluation

small study. Nurses
may not be
reflective of general
practice since 54%
had BS, and 44%
oncology certified.
Questionnaire may
have reflected more
perceived practice
than actual and may
have prompted
more consideration
of PN assessment

Jensen
Pharma/Millennium
Pharma
Published studies
only used abdomen
and thighs for SC
bortezomib. No
data on PK/PD in
other sites (arm)
demographics and
BSA does not
impact PK/PD SC
vs IV.
Support PICO
hypothesis

none

SC bortezomib has
less PN than IV.
Benefit to nursing
practice,
applicability to
contextual practice
is important given
study indicating
need for more
knowledge about
assessment and PN
not frequently
assessed.
Support PICO
importance of SC
for improved
patient outcomes
and nurse sensitive
outcomes.
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Article Title

Author, year,
Journal

13
Subcutaneous
versus intravenous
administration of
bortezomib in
patients with
relapsed multiple
myeloma: a
randomized, phase
3, non-inferiority
study.

14
Comparison of
pegfilgrastim
prescribing practice
to national
guidelines at a
university hospital
outpatient oncology
clinic

Moreau, P.,
Pylpinko, H.,
Grosicki, S.,
Karamanesht, I.,
Lelu, X.,
Grishunina, M.,
Rekhtman, G.,
...Harousseau J-L
(2011 April 19)

Waters, G.E.,
Corrigan, P.,
Gatesman, M., &
Smith, T.J. (2012
Nov 6) Journal of
0ncology Practice
doi:
10.1200/J0P.2012.
000662 retrieved
from
http://jop.ascopubs.
org/content/early/20
12/11/06/J0P.2012.
000662?papetoc
none

Lancet Oncology
12, 431-440
D0I:10.1016/S1470
- 2045(11)70081-X
Data Base & Key
Words

MedLine
subcutaneous
bortezomib, Phase 3
randomized

Research Design

Phase III, open
label, randomized

Level of Evidence
Study Aim/Purpose

II
compare efficacy

Retrospective
medical record
review
VI
Determine if

15
Subcutaneous
alemtuzumab in
fludarabine
refractory chronic
lymphocytic
leukemia: clinical
results and
prognostic marker
analysis from the
CLL2H stud of the
German chronic
lymphoma
leukemia study
group
Stilgenbauer, S.,
Zenz, T., Winkler,
D., Buhler A.,
Schlenk, R.F.,
Groner, S., Busch
R., Hensel, M.,
...Dohner, H. (2009
August 20) Journal

o f Clinical
Oncology 27(24).
3994-4001
Doi:10.1200/JC0/2
008.21.1128
Medline
Subcutaneous
chemotherapy
=3,424
Subcutaneous
versus intravenous
= 107
Administration
procedure = 47
Alemtuzumab = 4
Bortezomib = 3
Trastuzumab = 1
Phase II safety and
efficacy of SC
alemtuzumab
III
Evaluate safety,
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and safety of SC
administration to
standard IV
administration
Methods/ Study
Appraisal

2:1 randomization
of 222 relapsed
MM patients in 53
centers in 10
countries in Europe,
Asia and
SoAmerica. SC =
148 IV = 74.

Primary
Outcomes/Measures
/Results

non-inferiority in
overall response
rate as defined by

pegfilgrastrim is
overprescribed in
order to maintain
quality and reduce
costs
Record review of
292 patients, 124
evaluated and 88
included for study.
Descriptive
statistics

37% had no risk
factors, 22% had
one risk factor,

efficacy and clinical
biomarker impact
on outcomes

109 patients
enrolled (intent to
treat) 103
evaluable. After IV
dose escalation, SC
administered 3 x
week for up to 12
weeks, response
evaluated every 4
weeks during
treatment.
Progression Free
Survival (PFS)
defined from first
drug administration
to disease
progression, Overall
Survival (OS) time
from first drug to
death, data censored
for patients alive at
last follow up. Time
to Treatment failure
(TTTF) from first
drug to disease
progression, next
treatment or death.
Kaplan Meier
estimation of
response duration,
CI based on
cumulative hazard.
Survival
distribution by log
rank, Cox hazard
regression for
variables. Biologic
markers by FISH.
OR 39% (CR 4%,
PR 30%) Median
PFS 7.7 mos,
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retaining 60% of IV 46% of doses were
avoidable. Cost to
treatment effect.
OR of 35% in both health care system
arms or greater for a was $712, 264 in 1
80% power and one year
sided alpha of
0.025. Time to
event with Kaplan
Mier, adverse
events in all
patients receiving at
least one dose

Median OS 19.1
mos.
Toxicity profile
similar to IV
administration w
mild injection site
reactions

Author
Conclusions/
Implications of Key
Findings

OR after 4 and 8
cycles were
identical in SC and
IV arms. Adverse
events were similar
in both arms
EXCEPT peripheral
neuropathy was
lower in SC than IV
arm (5% vs 15%).
PK/PD reflect
similar AUC and
Cmax 10 times
longer with SC.

Approximately 50%
of pegfilgastrim use
did not follow
NCCN or ASCO
guidelines for use.
Changing practice
will reduce cost
without harming
patients

SC as effective and
save as IV data in pt
population. “ SC
should be preferred
delivery route
because o f efficacy,
convenience,
improved adverse
effect profile, and
cost savings” p. 394

Strengths/limitation
s

Large multi
centered
international study.
Limitations, no U.S.
sites. No patient
reported outcomes
to support benefit of
SC from patient
perspective

Retrospective chart
review in one
institution.
Prescribers
background not
identified.
Prescribers
knowledge of
guidelines not
addressed

Clinical trial does
not describe how or
where SC
administered

Source of Funding

Johnson & Johnson
& Millennium
Pharma

Comments

Pivotal data
supporting use of
SC bortezomib as
being effective with

Support PICO
hypothesis that
guidelines may not
be followed even

Support PICO
hypothesis of lack
of data on how to
administer SC
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less PN. Provides
guidance on
dilution and
administration of
SC formulation at
2.5mg/ml vs. 1:1
concentration.
Administration sites
only in abdomen
and thigh.

when published.
Adherence to
guidelines can
reduce costs
without patient
harm.

chemotherapy.

16
Knowledge,
attitudes and
practice behavior of
oncology advanced
practice nurses
regarding advanced
care planning for
patients with
cancer.

17
Subcutaneous
administration of
bortezomib:
strategies to reduce
injection site
reactions

18
Using the Theory of
Planned Behavior to
predict nurses'
intention to
integrate research
evidence into
clinical decision
making.

Zhou, G., Stoltzfus,
J.C., Houldin, A.D.,
Marks, S.M., Swan
B.A. (2010
November)
Oncology Nursing
Forum 37(6) p
E400-E410
doi:10.1188/10.ON
F.E400-E410

Kurtin, S., Knop,
C.S. & Milliron, T.
(2012, Nov/Dec)
Journal of
Advanced Practice
Oncology 3(6) 406
410
). Journal o f

Cote, F., Gagnon,
J., Houme, P.K.,
Abdeljelil, A.B,
Cagnon, M-P.
(2012)
Journal of
Advanced Nursing
68(10)2289-2doi:
10.1111/j.13652648.2011.05922.x
298

Data Base & Key
Words

ONS.org oncology
nurses knowledge,
practice, theory of
planned behavior,
valid practice
survey

CINHAL
subcutaneous
bortezomib, nurse,
administration,
injection

CINHAL,Wiley
Online; Theory of
Planned Behavior,
clinical decisions,
apply evidence

Research Design

descriptive, cross
sectional pilot

Opinion of author

predictive
correlational study

Article Title

Author, year,
Journal

Advanced.
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survey
Level of Evidence
Study Aim/Purpose

VI
establish reliability,
validity of web
based survey on
nurses knowledge,
attitudes and
practice, gain
understanding of
nurses knowledge
and perceived
barriers to practice

Methods/ Study
Appraisal

One author
developed questions
based on Theory of
Planned behavior,
using questions
from other surveys,
own clinical
expertise and input
from practice
experts. Initial
survey evaluated by
6 APNs, then sent
to 300 APNs. 89
included in final
analysis. After 30
40 days re-test
survey sent to 89
respondents. 53
completed.
Information loaded
onto excell and
coded then put into
SAS for stats.
Descriptive stats for
demographics,
Factor analysis for
questions for test
and re-test with
Cornbach alpha for
5 factors to validate
questionnaire. "Resu
lts revealed a sta-

VII
Review of SC
Phase III study.
Provide
recommendation for
SC administration
technique

n/a

VI
identify factors that
influence nurses
intention to adopt
research into
practice

questionnaires sent
to nurses in one
hospital. 336
questionnaires
analyzed. Sample
size was deemed
adequate due to
being 10 times
higher than number
of varialbes in the
regression model.
Institution was
University setting
with wide variety of
settings.
test-retest to
validate
questionnaire.
Added two
elements to TPB 1.
past behavior and
moral norm based
on research done by
authors. Descriptive
statistics for mean
and SD of
scores,Pearsons
correlations
between outcome
variable = intention
and independent
variables, multiple
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tistically significant
correlation between
the two surveys (r =
0.74, p < 0.0001),
thereby providing
preliminary
evidence of testretest reliability." (p
E405)

linear regression to
identify variables
that predict nurses
intention to use
research in practice
and between beliefs
and intentions ,

Primary
Outcomes/Measures
/Results

Knowledge of
advanced care
planning: average
score was 67% (33
92%). In general
participants scored
positively in
attitudes about
advanced care
planning, only
marginally positive
in practice of
incorporating
advanced care
planning. Barriers
included family not
ready, physicians
reluctant, staff
discomfort and
time.

Recommendations:
Site seletion
Air sandwich

Intention predicts
behavior and is
based on attitudes
(behavior beliefs),
subjective norms
(normative beliefs)
and perceived
control (control
beliefs). Study
suggests moral
norms, perceived
behavioral control,
normative beliefs
and past behaviors
predict intention.

Author
Conclusions/
Implications of Key
Findings

Established
construct validity of
survey items
assessing nurses
knowledge of
advanced care
planning. Nurses
moderately
knowledgeable, and
with positive
attitudes. Study
outcomes similar to
literature for APNs
and MDs

Need to develop
practice guideline
for SC bortezomib
admniistration

Interventions to
change behaviors
need to be relevant
to specific nursing
practice and within
the context of the
practice. Behavior
beliefs are not
associated with
intentions,
subjective norms
are least associated
with behavior,
moral norm and
past behavior are
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most associated
with intention and
behavior
Strengths/limitation
s

small sample. Need
5 - 10 respondents
per item & other
analytics to validate
survey

Source of Funding

Not indicated

Comments

Theory of Planned
Behavior (TPB)
valid for capstone
in identifying
perceptions and
practice.

Very limited
references utilized.
References for air
sandwich based on
authors articles, not
reference
Non indicated

Supports need to
develop SC
injection guidelines.
Need for more
literature review

small sample at one
French Canadian
institution

Canadian Institutes
of Health Research
Strong article to
support TPB in
considering how
nurses intent to use
SC procedure.
Reinforce nurses
have important role
in pt outcomes
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Article Title

Author, year,
Journal

19
Understanding
adherence to hand
hygiene
recommendations:
the Theory of
Planned Behavior.

20
Clinicians’
perceptions about
use of computerized
protocols: a
multicenter study

21
Subcutaneous
injection technique

O'Boyle, C.A.
Henley, S.J.,
Larson, E. (2001)
Am J Infection
Control 29; 352-260

Phansalkar, S.,
Weir, C.R., Morris,
A.H. & Warner,
H R. (2008)

Hunter, J (2008
January) Nursing
Standard. 22(21)
41-44

International
Journal o f Medical
Informatics 77.

Data Base & Key
Words

CINHAL, Theory
of Planned
Behavior, nurse,
adherence,
procedures

184-193
MedLine
Clinician
perceptions = 405
Clinical protocols
Decisions = 4

Research Design

longitudinal,
observational

Semi structured
interviews

none

Level of Evidence
Study Aim/Purpose

VI
Estimate adherence
to hand washing
recommendations;
describe
relationship
between
motivational
factors, adherence
and intensity of
nursing activity to
handwashing; test a
model for
adherence based on
TPB

VI
Develop and
validate instrument
for assessing
clinicians
perceptions about
computerized
protocols

VII
Describe principles
and technique for
SC injections to
update nurses’
knowledge and
skills

Methods/ Study
Appraisal

120 nurses in
critical care and
post critical care
unit s in 4
Minneapolis

Two stage:
1. semi
structured
interviews
to identify

N/A

CINHAL
subcutaneous
injection, technique,
drug administration
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hospitals.
Nurses completed
Hand washing
Assessment
Inventory, 2 weeks
- 4 months later
were observed in
practice for
adherence to
guideline.
Descriptive
statistics and
correlation statistics

Primary
Outcomes/Measures
/Results

1246 indications for
handwashing,
adherence 70% (61
74%) vs self
reported adherence
of 82% (71-89%)
p=0.0001. High
correlation between
motivational factors
and intentions, but
not w observed
adherence

Author
Conclusions/
Implications of Key
Findings

Predicting
handwashing
adherence only
occurred in the

themes
2. 2. Item
generation
for
instrument;
administer
instrument
needed 5
participants
per item for
power =
sample size
175; factor
analysis
using
Varimax
rotation and
scree plots;,
scale
construction
Cornbachs
alpha 0.70
or higher;
construct
and
predictive
validity
Pearsons
correlation
82% response rate
240 clinicians (53
physicians, 132
nurses, 55 resp.
therapists)
29 of 35 items
retained

Results provide a
theorectical
framework for
assessing clinical

N/A

Step by step
approach with
rationale for the
steps .
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context of specific
nursing activities,
and not related to
motivational
variables from the
TPB.

perceptions about
computerized
protocols
Strongest predictor:
Beliefs regarding
self-Efficacy.
Literature review of
barriers to guideline
adherence:
Knowledge,
attitudes and
external barriers.
Making clinicians
understand why
protocols are
important for
patient outcomes
will improve
intentions for use.
Based on Nursing
and Midwifery
Council (UK).

Strengths/limitation
s

Important study.
Small sample size,
self selected
participants, no
control for
institutional
confounding
variables

Source of Funding

Georgetown
University School
of Nursing, 3M
Enrich Program,
Association of
Professionals in
Infection Control
Research
Association

NIH/NHLBI ARDS

Comments

Must focus on
individual in
specific context and
situation, rather
than on theoretical
situation. Perceived
control and past
behavior can predict

Based on Theory of
Planned Behavior.
Factors influencing
perceptions:
Beliefs regarding
self-efficacy,
environmental
support, role

Does NOT discuss
changing needle
before
administration,
important for
chemotherapy
administration.
Does provide
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Article Title

Author, year,
Journal

Data Base & Key
Words

Research Design
Level of Evidence
Study Aim/Purpose

intention and
behavior. Project
should address SC
in context of clinic
setting and past
experiences

relevance, work
importance, beliefs
regarding control,
attitude towards
information quality,
social pressure,
culture and
behavioral intention

rationale for sites
including the arm
for SC

22
Management
guidelines for the
use of aletuzumab
in chronic
lymphocytic
leukemia
Ostergorg, A., Foa,
R., Bezares, R.F.,
Dearden, C., Dyer,
M.J.S., Geisler, C.,
Lin, T.S., Montillo,
M., van Oers,
M.H.J., Wendtner,
C-M., (2009)
Leukemia 23. 1980
1988 doi:
10.1038/leu.2009.1
46
MedLine
Subcutaneous
chemotherapy,
administration

23
Likert scales and
data analysis

24
Likert scales, levels
of measurement and
the “laws” of
statistics

Allen, I.E.,
Seamona, C.A.
(2007) American

Norman, G. (2010)

Consensus review
VII
Update 2004
recommendations
based on clinical
data

Society for Quality.
Retrieved from
http://asq.org/qualit
yprogress/2007/07/st
atistics/likert-scales

Medline
Survey instruments,
design, Likert
scales, ANOVA,
ordinal statistics
methods
None
N/A
Overview o f use of
likert scales for
rating surveys.

Advances in Health
Science Education
15. 625-632. Doi:
10.1007/s10459010-922-y

MedLine
Likert scales, data
analysis,

none
n/a
Challenges
argument that
parametric methods
cannot be used with
ordinal data from
Likert scales.
Review of
assumptions of
various statistical
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Methods/ Study
Appraisal
Primary
Outcomes/Measures
/Results

Author
Conclusions/
Implications of Key
Findings

Consensus of
experts
1. monotherapy can
be used as front line
2. describes suitable
subgroups of
elderly, 3.
Treatment should
continue fo r12
weeks, 4. Mandate
CMV monitoring
by PCR, 5. SC IS
SAFE, EASY AND
EQUALLY
EFFICACIOUS. 6.
Combination and
consolidation
should only be used
in clinical trials.

See above

N/A
Likert scales should
NOT involve
parametric statistics
but should rely on
the ORDINAL
nature of the data (p
3). Scales with even
numbers force rank
by eliminating the
neutral option.

Mean and standard
deviation are
INVALID for
descriptive stats
from an ordinal
scale. NONPARAMETRIC

methods and the
problems when
assumptions are
violated (p 627)
n/a
Sample Sizes:
Small sample size
may be an issue that
is unrelated to
choice of statistical
test. Too small
sample challenges
validity of being
representative
EXCEPT in
qualitative studies.
Small size may
cause concern about
distributions.
HOWEVER the
demarcation is 5 per
group.
Normal distribution
is based on the
normality of the
distribution of the
means, not the data.
Therefore, ANOVA
can be used. The
Central Limit
Theory indicates for
samples greater
than 5 or 10 per
group, the means
are approximately
normally
distributed.
“Parametric
statistics can be
used with Likert
data, with small
sample sizes, with
unequal variances
and with non-
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Strengths/limitation
s

Source of Funding

Comments

Based on data on
over 20,000 patients
in clinical literature
and NCCN
guidelines.
Limitation, expert
panel opinion
Conflict of interest:
all authors had
received honoraria
from Bayer Pharm
Although SC is
deemed safe,
effective and easy
to give, there is no
direction on how to
administer the drug.

procedures based on
rank, median or
range, or
distribution free
methods such as
tabulations,
frequencies,
contingency tables
and chi squared
statistics are
appropriate.
Kruskall Wallis can
be used for analysis
of variance.
Brief summary of
likert scales and
appropriate
statistics

normal
distributions”

Useful for
designing survey
statistics

Provided
clarification for
validation of
instrument articles
that indicated 5
respondents per
question was
needed. Provided
confusion about
what statistics to
use for survey.
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Article Title

Author, year,
Journal

25
Oncology nurses’
perceptions about
involving patients
in the prevention of
chemotherapy
administration
errors
Schwappach,
D.L.B.,
Hochreuetener, M 
A, Wernli, M.,
(2010 March)

Oncology Nursing
Forum 37(2) E84-

Data Base & Key
Words

Research Design
Level of Evidence
Study Aim/Purpose

Methods/ Study
Appraisal

E91 doi:
10.1188/10.ONF.E8
4-E91
CINHAL,
Academic
SearchPremier,
Eric, MedLine
Mixed methods
design nurs* =
1,217
And oncology nurs
= 45
Perception
chemotherapy= 20
Descriptive
qualitative
VI
Explore nurses’
attitudes, and
experiences toward
patients
participation in
preventing chemo
administration
errors

Focus group
discussion of 11
oncology nurses

26
Nursing -sensitive
patient outcomes description and
framework

27
Qualitative data
analysis for health
services research:
developing
taxonomy, themes
and theory

Given, B., Beck, S.,
Etland, C., Holmes
Gobel, B., Lamkin,
L., & Marsee, V.D.
(2005) Retrived
from
http://www.ons.org/
Research/NursingSe
nsitive/ Description

Bradley, E.H,
Curry, L.A., &
Devers, K.J. (2007)

Health Services
Research 42, 1758
1772
doi: 10.1111/j.14756773.2006.008684.
x

ONS.org
Nurse sensitive
outcomes defined

MedLine,
Academic Search
Premier, CINHAL,
Eric
Qualitative data
analysis health
care= 7,842
Developing themes
= 187

White paper

None -

VII
Provide definition
for nursing sensitive
outcomes in support
of ONS
commitment to
quality and
defining,
measuring, and
educating about
nursing sensitive
outcomes.
Expert panel
consensus

Provide practical
strategies for
analyzing
qualitative data

“describe an
approach to
qualitative data
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Primary
Outcomes/Measures
/Results

from a large
Swedish
community
hospital. 6 nurses
from outpatient
oncology , 5 from
inpatient setting.
First focus group
discussed
experiences with
patients, attitudes,
and nurses’ role in
engaging patients in
safety. Second
session with same
group 10 weeks
later themes were
observations and
experiences,
anticipated or
perceived changes
in relationships,
responses and
interventions.
Sessions recorded
and transcribed
verbatim, inductive
theme-identification
content-analysis
framework applied
to transcripts,
categories
abstracted, iterative
process to organize
into themes. Results
and interpretations
discussed with
focus group
participants for
member checking
Four major themes
emerged
Involving patients;
challenges, strains
and barriers;
Responsibility for

analysis that applies
the principles of
inductive reasoning
while also
employing
predetermined code
types to
guide data analysis
and interpretation.
These code types
(conceptual,
relationship,
perspective,
participant
characteristics, and
setting codes)
define a structure
that is appropriate
for generation of
taxonomy, themes,
and theory.
Conceptual codes
and subcodes
facilitate the
development of
taxonomies”

Outcomes must
address short,
intermediate and
long-term
interventions.
Measurements must

Describe ways to
develop and
measure codes.
Generating results
through taxonomy,
themes and theory
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safety; and learning
and reflecting on
patient
involvement. (p
E86) May
participants
changed behavior
between focus
groups

Author
Conclusions/
Implications of Key
Findings

Strengths/limitation

“Active
involvement of
patients in safety
requires cultural
and organizational
change” for
success.
“Chemotherapy
administration
procedures should
be standardized to
allow patients to
detect deviations
from routine.” (p
E89) TPB self
efficacy, behavioral
control beliefs and
perceived
effectiveness of
actions supported in
article.
Single institution

take place at
expected time of
outcome from
intervention.
Outcomes
indicators are
patient focused and
provider focused.
Provider focused
outcomes relate to
provider
proficiency,
knowledge, skill,
self-confidence,
turnover, priority
satisfaction and
caregiver demands.
Provider practice
activities affect
patient outcomes,
including
complications and
provider
effectiveness
Classification of
Oncology NSO:
Symptom
experience
Functional status
Safety
Psychological
distress
Economic

Provides exemplars

“Qualitative
research
methodologies can
generate rich
information about
health care
including, but not
limited to, patient
preferences,
medical decision
making, culturally
determined values
and health beliefs,
consumer
satisfaction,
health-seeking
behaviors, and
health disparities”

89

Subcutaneous Bortezomib
s

Source of Funding

Comments

with subjects from
two very different
practice
environments and
experiences. Small
number. Did not
describe saturation
Grant from
Oncosuisse

for NSOs. White
paper from small
group of experts

Key article to
consider for
qualitative
component of
project. Supports
patient role in
administration and
importance of
nurses consistency
in administration
procedures to
ensure patient
safety and
confidence in
nursing procedures.

Oncology nurses
skills, knowledge
and competence can
influence SC
administration and
adverse events.

ONS

Patrick and
Catherine Weldon
Donaghue
Medical Research
Foundation and the
Claude D. Pepper
Older Americans
1768 HSR: Health
Services Research
42:4 (August 2007)
Independence
Center at Yale
University
Provides guidance
for developing
themes from project
interviews in order
to describe nurse
perceptions and
decisions about
administering SC
chemo
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Article Title

Author, year,
Journal

28
Three approaches to
qualitative content
analysis

29
Mixed methods
research
methodologies

Hsieh, H.F., &
Shannon, S.E.
(2005) Qualitative

Terrell, S.R (2012
Janurary)

Health Research.

The Qualitative
Report 17(1) 254

15, 1277-1288 doi:
10.1177/104973230
5276687

280
http://www.nova.ed
u/ssss/QR/QR171/terrell.pdf

Data Base & Key
Words

Same as previous

Eric
Mixed methods,
qualitative research,
methodology

Research Design
Level of Evidence
Study Aim/Purpose

none

None

Delineate
procedures to
analyze three
approaches for
content analysis in
qualitative design

Provide an
overview of mixed
methods in health
care research

“identified three
distinct approaches:
conventional,
directed, and

Overview and
background

Methods/ Study
Appraisal

30
Methodological
reporting in
qualitative,
quantitative and
mixed methods
health services
research articles
Wisdom, J.P.,
Cavalerie, M.A.,
Onwuegbuzie, A.J.,
& Green, C.A.
(2012 April) Health

Services Research.
47(2) 721-745
DOI:
10.1111/j.14756773.2011.01344.x
MedLine,
Academic Search
Premier, Eric
Mixed methods,
health care
Literature summary
VII
describes the
frequency of mixed
methods in
published health
services research
and compares the
presence of
methodological
components
indicative of
rigorous approaches
across mixed
methods,
qualitative,
and quantitative
articles.
Reviewed empirical
articles from 4
journals and
determined if
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summative. All
three approaches
are used to interpret
text
data from a
predominately
naturalistic
paradigm”
Utilized
hypothetical data
drawn from end-oflife care

Primary
Outcomes/Measures
/Results

“Key differences
among
conventional,
directed, and
summative
approaches to
content analysis
center on how
initial codes are
developed.
In a conventional
content
analysis, categories
are derived from
data during data

Four factors
determine
approach:
Theoretical
perspective:
explicitly based on
theory or implicitly
indirectly based on
theory
Priority:
Quantitative or
qualitative primary
Sequence of data
collection:
qualitative or
quantitative first or

qualitative,
quantitative or
mixed design.
“Random samples
of
qualitative and
quantitative articles
were selected using
a random number
generator and did
not adjust for
journal or year
assessed the
frequency of
key methodological
components
reported across
articles, then
compared rates
by article type.” (p
727)
articles were coded,
conducted a
statistical analysis
to determine
whether there were
trends over time in
the prevalence of
mixed methods
articles.
Research Question
1: How has the
frequency of mixed
methods studies
published
in health services
journals changed
over time?
from 2003 through
2007. Only 2.85
percent (n = 47) of
empirical articles
were mixed
methods studies;
6.18 percent
(n = 102) of
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analysis. The
researcher
is usually able to
gain a richer
understanding of a
phenomenon with
this approach.
W ith a directed
content analysis, the
researcher uses
existing theory or
prior research
to develop the
initial coding
scheme prior to
beginning to
analyze the data.
The summative
approach to content
analysis is
fundamentally
different from the
prior two
approaches.
Rather than
analyzing the data
as a whole, the text
is often approached
as
single words or in
relation to particular
content. An analysis
of the patterns leads
to
an interpretation of
the contextual
meaning of specific
terms or content”

none
Point of data
integration:
At data analysis, at
data interpretation
or combination

empirical studies
represented
qualitative research.
Quantitative
research
represented 90.98
percent (n = 1,502)
of empirical
articles. All journals
combined published
an average of 10.8
mixed method
articles per year, or
3.27 percent of
empirical articles
annually.
A quadratic trend
was seen across the
5 years (R2 = 0.65),
indicating a slight
increase in mixed
method articles in
the first 2 years and
then a decrease for
the remaining
years.” (p 729)
Research Question
2: How are mixed
methods articles
being used to
elucidate
health services
research?
Mixed methods
articles were
categorized into
four overlapping
categories:
Articles on
organizational and
individual decision
making processes
(n = 18 studies)
combined
qualitative
interviews with
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quantitative
administrative
data analyses to
assess decision
making about
processes or
impediments
to processes (p
730)
Author
Conclusions/
Implications of Key
Findings

The question of
whether a study
needs to use a
conventional,
directed, or
summative
approach to content
analysis can be
answered by
matching the
specific research
purpose and the
state of science in
the area of interest
with the appropriate
analysis technique”
(p 1286)

“there are
established rules for
controlling validity
in standard
quantitative and
qualitative research.
These same rules
must be followed
when the methods
are combined.” (p
274)

Mixed methods
provide more
comprehensive
picture than the two
methods alone.
However, care must
be taken to use
rigorous
methodologies
“Whatever
frameworks are
used, it is essential
that authors who
engage in mixed
methods research
studies meet two
primary goals
(developed
by the American
Educational
Research
Association 2006):
Mixed methods
researchers should
(1) conduct and
report research that
is warranted or
defensible
in terms of
documenting
evidence,
substantiating
results, and
validating
conclusions; and (2)
ensure that the
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Strengths/limitation
s

Source of Funding

. not indicated

Not indicated

Comments

My assumption is a
conventional
content analysis
would be
appropriate for the
project

Assume project
will use implicit
theoretical approach
based indirectly on
theory of planned
behavior.
Quantitative data
will have priority
over qualitative.
Data will not be
collected in
sequence.
Am not sure about
data analysis

31
A 4 mm needle
reduces the risk of
IM injections
without increasing
backflow to skin
surface in lean
diabetic children
and adults
Birkebaek, N. H.,
Solvig, J.,
Jorgensen, C.,
Smedegaard, J., &
Christiansen, J. S.
(2008, September).

32
Evaluation of skin
and adipose tissue
thickness for
optimal insulin
injection.

Article Title

Author, year,
Journal

Diabetes Care,
31(9), e65.

Akkus, O., Oguz,
A., Uzunlulu, M., &
Kizlgul, M. (2012).

Journal Diabetes
Metabolism, 3(8).

conduct of research
is transparent in
terms
of clarifying the
logic underpinning
the inquiry” (p 740)
Review of over
1,000 articles.
Literature review,
not systematic
review applied to
only four journals
National Institute
on Drug Abuse
Mixed method
useful for
describing decision
making process
such as procedure
for SC and site
preference.
However, following
rigorous methods
may be challenge a
priori

33
Effect of injection
duration on bruising
associated with
subcutaneous
heparin: a quasiexperimental
within-subject
design
Akpinar, R. B., &
Celebioglu, A.
(2008).

International
journal o f Nursing
http://dx.doi.org/10. studies 45, 812-817
4171/2155
6156.1000216
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Data Base & Key
Words

Research Design
Level of Evidence
Study Aim/Purpose

Methods/ Study
Appraisal

http://dx.doi.org/
MedLine SC,
needle size

Descriptive
intervention
VI
Measure distance
from from skin to
muscle in lean DM
pts and use of 4 mm
needle to reduce
frequency of IM
compared to 6 mm
21 lean children /
32 lean adults

MedLine SC,
adipose thickness,
needle size
Case control
IV
Compare skin and
SC adipose tissue
between health
controls and DM
pts and associates
BMI and waist
circumference

Primary
Outcomes/Measures
/Results

No distance < 4 mm
from skin to fascia
in abdomen or
thigh.

Highest skin and
adipose tissue
thickiness
associated with
higher waist
circumference and
BMI

Author
Conclusions/
Implications of Key
Findings

4 mm needles
reduce risk of IM
can inject without
elevated skin fold
using 90 degree
angle in thigh
Use 45 degree angle
and skin fold with 6
mm needle in thin
pts

Largest skin
thickness 3.92 mm
Short needles
appropriate in pts w
> BMI
Average skin
thickness
Arm: 1.95 mm
Abdomen 2.35 mm
Thigh 1.97 mm
SC adipose tissue
Arm 6.42 mm
Absomen 15.73
Thigh 7.92

Strengths/limitation
s
Source of Funding
Comments

Small study,
abstract summary
Novo Nordisk
Supports use of

Use of needles >

CINHAL
SC injection
duration site
reactions
Quasi-experimental
IV
Compare the effects
of 3 SC injection
durations on
bruising

36 subjects received
3 injections from
same investigator
using 3 techniques
descriptive statistics
30 second injection
and waiting 10
seconds before
withdrawing after
10 second injection
resulted in less
bruising than 10
second
Slow injection
causes low
pressure, less
trauma. Waiting to
withdraw needle
may allow
absorption.

Evidence of nursing
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Article Title

Author, year,
Journal

needles < 5mm for
SC

6mm without
pinching skin or
with 90 degree
angle may = IM

practice to decrease
bruising
30 sec injection OR
10 sec injection
leaving needle in
for 10 sec

34
A study on the
effect of the
duration of
subcutaneous
heparin injection on
bruising and pain

35
Does needle size
matter?

Zaybak, A., &
Khorshid, L. (2007
Journal of Clinical
Nursing 378-385
doi.org/10.111/j.13
65
2702.2006.01922

Gill, H. S., &
Prausnitz, M. R.
(2007, September).

36
Skin and
subcutaneous
adipose layer
thickness in adults
with diabetes at
sites used for
insulin injections:
implications for
needle length
recommendations
Gibney, M. A.,
Arce, C. H., Bryon,
K. J., & Hirsch, L.
J. (2010). Current

Data Base & Key
Words

CINHAL
SC, pain, bruising,
duration,

Research Design

Quasi experimental
within patient
IV
Determine effect of
injection duration
on bruising and
pain
50 pts SC heparin
administered 10
seconds and 30
seconds Visual
Analog Scale to
measure pain
10 second injection

Level of Evidence
Study Aim/Purpose

Methods/ Study
Appraisal

Primary

Journal o f Diabetes
Science adn
Technology, 1(5),

Medical Research
& Opinion, 26(6),

725-729.

1519-1530.

CINHAL
SC needle size,
needle gauge, pain,
needle insertion
Review article
VII
Review
development of
smaller needles

Likelihood of pain
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Outcomes/Measures
/Results

= 64% bruising
30 second = 42%
pain significantly
lower with 30 sec
vs 10 sec

Author
Conclusions/
Implications of Key
Findings
Strengths/limitation
s
Source of Funding
Comments

Article Title

Author, year,
Journal

Duration has effect
on bruising and
pain

Extend injection
duration

Needle tip
sharpness,
lubrication can
reduce the force of
insertion
Suggests rationale
for needle change
after drawing up
medicatioin

37
Performing
subcutaneous
injections: a
literature review.

38
Adherence to
therapy: Using an
evidence-based
protocol

Annersen, M., &
Wilmann, A. (2005,
Third Quarter).

Moore, L. A.,
Kaufman, M. D.,
Algozzine, R., Irish,
N., Martin, M., &
Posey, C. R. (2007,
November/Decemb
er). Rehabilitation
Nursing, 32(6),
227-232.

Worldviews on
Evidence-Based
Nursing, 122-130.

Data Base & Key
Words
Research Design

and bruising
decreases with
higher gauge
needles
Mechanics of
needle insertion,
force of insertion
also impacts pain

Systematic Review

39
Evaluation of
bruises and areas of
induration after two
techniques of
subcutaneous
heparin injection
Wooldridge, J. B.,
& Jackson, J. G.
(1988, September).
Heart & Lung 17(5)
476-482
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Level of Evidence
Study Aim/Purpose
Methods/ Study
Appraisal
Primary
Outcomes/Measures
/Results
Author
Conclusions/
Implications of Key
Findings
Strengths/limitation
s
Source of Funding
Comments

I

Most significant
reference: Need to
describe what
nurses are doing

Evidence for air
sandwich and dry
needle

Change needle and
use of air bubble

40

41
Randomized
clinical trial to
assesspain and
brising in medicines
administered by
means of
subcutaneous and
intramuscular
needle injections: is
it necessary to have
needles changed?
Lamblet, L. C.,
Meira, E. S.,
Ferreira, B. C., &
Mathucchi, S. D.
(2011,
September/October)
. Latino-American
Enfermagen, 19(5),
1063-1071.

42
Effects of changing
needles prior to
administering
heparin
subcuatneously.

Article Title
Management
strategies for
improving the
tolerability of
interferons in the
treatment of
multiple sclerosis.

Author, year,
Journal

Data Base & Key
Words
Research Design
Level of Evidence
Study Aim/Purpose
Methods/ Study

Girouard, N., &
Theoret, G. (2008).
Canadian Journal of
Neuroscience
Nursing 30(4) 18
24

Kingman, L. (2000,
Jan-Feb). Heart
Lung, 29(1), 70-75.
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Appraisal
Primary
Outcomes/Measures
/Results
Author
Conclusions/
Implications of Key
Findings
Strengths/limitation
s
Source of Funding
Comments

Article Title

Author, year,
Journal

Site rotations and
needle change

RCT no advantage
to needle change

No decrease in
bruising w needle
change

43
Patient education:
Giving a
subcutaneous
injection.

44
New injection
recommendations
for patients with
diabetes.

National Institutes
of Health. (2012).
www.cc.nih.gov/cc
c/pati ent_educati on/
pepubs/subq.pdf

Frid, A., Hirsch, L.,
Gaspar, R., Hicks,
D., Kreugel, G.,
Liersch,
J.,...Strauss, K.
(2010).

45
Higher incidence of
injection site
reactions after
subcutaneous
bortezomig
administration on
the thigh compared
with the abdomen
Kaminura, T.,
Miyamoto, T.,
Yokota, N.,
Takashima, S.,
Chong, Y., Ito, Y.,
& Akashi, K.
(2012). European J
Heamatology
http://dx .doi .org/10.

Diabetes &
Metabolism, 36, S3S18.

1111/ejh.12
055

Data Base & Key
Words
Research Design
Level of Evidence
Study Aim/Purpose
Methods/ Study
Appraisal

Systematic review
I
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Primary
Outcomes/Measures
/Results
Author
Conclusions/
Implications of Key
Findings
Strengths/limitation
s
Source of Funding
Comments

5/8 inch needle

Short needle,
change needle
purge
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Article Title

Author, year,
Journal

Data Base & Key
Words
Research Design
Level of Evidence
Study Aim/Purpose
Methods/ Study
Appraisal
Primary
Outcomes/Measures
/Results
Author
Conclusions/
Implications of Key
Findings
Strengths/limitation
s
Source of Funding

Comments

46
Pain following
controlled
cutaneous insertion
of needles with
different diameter
Arendt-Neilsen, L.,
Egekvist, H., &
Bjerring, P. (2006,
March/June).

47
Evidence-based
practice guidelines:
A survey of
subcutaneous
dexamethasone
administration.
Walker, J., Lane, P.,
& McKenzie, C.
(2010).

Somatosensory and
Motor Research,

International
Journal of
Palliative Nursing,

23(1/2), 37-43.

16(10), 494-498

48
New injection
recommendations
for patients with
diabetes.

Frid, A., Hirsch, L.,
Gaspar, R., Hicks,
D., Kreugel, G.,
Liersch,
J.,...Strauss, K.
(2010) Diabetes &
Metabolism, 36, S3S18.

Systematic review
I

Supports use of <5
mm needles

Supports need for
standard SC admin
guidelines in
palliative care

Recommends
needle change and
purge needle
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Article Title

Author, year,
Journal

Data Base & Key
Words
Research Design
Level of Evidence
Study Aim/Purpose
Methods/ Study
Appraisal
Primary
Outcomes/Measures
/Results
Author
Conclusions/
Implications of Key
Findings
Strengths/limitation
s
Source of Funding

Comments

49
Intramuscular
injections: To swab
or not to swab
Cocoman, A., &
Murray, J. (2010)
Retrieved from
http://www.inmo.ie/
MagazineArticle/Pri
ntArticle/6696

ETOH irritating,
not needed, if used,
must dry

50
WHO best practices
for injections and
related procedures
toolkit.
World Health
Organization.
(2010).

Does not
recommend ETOH
for SC injections
W ater cleanse
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Appendix B
The Subcutaneous Administration of Bortezomib Guideline Project Logic Model
Will the development of a standardized guideline for nurses who administer subcutaneous
bortezomib in community oncology practice settings lead to standardized practice when
administering this chemotherapy agent?
RESOURCES

ACTIVITIES

OUTPUTS

SHORT &
LONG-TERM
OUTCOMES

IMPACT

In order to
accomplish our
set o f activities
we will need the
following:

In order to
address our
problem or
asset we will
accomplish the
following
activities:

We expect that
once
accomplished
these activities
will produce
the following
evidence o f
service
delivery:

We expect that if
accomplished
these activities
will lead to the
following
changes in 1-3
then 4-6 years:

We expect that
if accomplished
these activities
will lead to the
following
changes in 7-10
years:

1 - 3 years:
Standard
guidelines for
SC bortezomib
will be
incorporated
into the clinical
literature as a
frameworkfor
standardizing
techniques in
community and
academic sites.
Hypothesis
generatingfor
pharmacokinetic
study to
evaluate PK of
injections in
arm ensuring
safe, effective
site selection
4 - 6 years:
Guidelines and

Patients staying
on effective
therapy with
reduced
adverse events
will obtain
maximum
benefit
including
responses and
survival.

A value
proposition
Champion
proposal for
stakeholder buy project
proposal
in
through
Identification
required
and acceptance
committees
o f cross
Submit and
functional
activate SOW
project team
for funding
(internal)
The
Subcutaneous
Administration
o f bortezomib
Survey (SABS)
Evaluate and
contact
potential study
sites

Contract with
clinics capable
ofparticipating
Obtain 2 way
CDA with
site(s)
Develop SABS
Submit SABS
for content
validity review
and amend as
needed

Identify and
select clinical
sites agreeing
to participate in
Submit SABS to
project

RNs will utilize
standard
guideline for
administering
SC bortezomib
relative to:
Site selection
Needle size
Changing
needles before
administering
injection
Use o f air
sandwich
technique
Duration o f
injection

Produce
exemplar for
pharmaceutical
companies to
describe how
drugs are
administered
during clinical
trials, in
addition to
standard
outcomes data.
Increased
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Budget for
study
Mechanism for
collecting data
from survey
instruments

legal
Obtain IRB
exemptions
Reformat SABS
to web based
survey format

Approvalfrom
Educate site
Global
coordinator,
Medical
explain and
Affairs, legal
provide cover
and compliance letter,
confidentiality
IRB exemption
agreement
and
Regis and
project process
Clinical
information
Network
Method to
identify nurses
meeting
eligibility
criterion

Establish
weekly contact
with site
coordinator

Receive Excell
spreadsheets
Mechanism to
with
present, explain
and encourage aggregated
data
participation
Review
spreadsheet for
missing data
Submit
spreadsheets to
biostatisticians,
indicating
missing data
points
Perform
content analysis
on qualitative
responses
Collaborate
with clinical
advisor to
identify themes
Analyze data

project will
become
hypothesis
generating for
clinical studies
to validate the
guideline results
in decreased
injection site
reactions and
pain. Supports
nurse sensitive
patient
outcomes of
managing
adverse events

inclusion of
nursing
outcomes
studies
incorporated
into clinical
trials for drug
development
Improved
patient
outcomes as
nursing
standards are
included and
described in
clinical trials.
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Present
descriptive data
and summary of
qualitative
themes to
advisors
Formulate
interpretations
of data for each
variable
Compare/
contrast data to
clinical
literature
Construct
guidelines for
each pertinent
variable based
on clinical
literature and
survey
responses
Draft practice
guideline for
SC
administration
o f bortezomib
Present data,
interpretations
and draft
guideline to
participating
network clinical
coordinators
for review,
discussion and
revisions
Develop final
guideline (2
additional
drafts)
Present,
explain and
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instructfinal
guideline to
network clinical
coordinators
Engage in
sessions to
recommend
methods for
implementing
practice
improvement
guideline and
monitor
acceptance
Follow up with
clinical
coordinators in
3 months to
evaluate
implementation
and acceptance
ofpractice
guideline
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Appendix C
Time Frame for Completion by August 2013

Aug 2012
Redefined
CapstoneProject
Approval DNP
Advisors

Nov 2012 - April
2013 Revisions
IRB document

Sept 2012- April
2013 Systematic
Review of
Literature
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Feb - March
2013 Develop
Survey
Instrument

March Survey
content
validated

March CCE
agrees to
project

April 9 DNP
Capstone
Presentation
& NE IRB
Approval

March 11
submit NE
IRB

Feb - April
Proposal
Paper
Writing

April 12 Regis
IRB
submitted
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May
Adapt
Survey to
web
format

^

June - July
Analyze &
interpret
data

May 20
launch
survey

• • • •
May Regis
IRB
approval

June 15
Close
Survey

August 12 Present
capstone project
for approval
Completion DNP
Program

July First Draft
Guideline
Presented to CCE

•

•
August finalize
paper

•
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Appendix D
Budget and Resources
Estimated budget for the project $23,000.
Direct Costs:
•

New England IRB $600

•

Survey Monkey subscriptions $204

•

Administrative support to convert survey to electronic format $300

Indirect costs:
Salary for project investigator time over 20 weeks (March through June 2013) for
approximately 15 hours per week (300 hours) at $73 per hour. Activities included:
•

Draft survey

•

Collaborate with content experts and redraft survey

•

Prepare IRB documents for New England and Regis University IRB

•

Consult with CCE on implementing survey

•

Supervise administrative assistant to translate paper document to web format

•

Weekly phone conversations with CCE manager o f research

•

Access final aggregated survey

•

Evaluate survey for completeness

•

Consult with statisticians to run SAS

•

Analyze quantitative responses

•

Analyze qualitative responses for themes

•

Compare survey results to literature

•

Develop draft guideline
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•

Review results and draft guideline with CCE

•

Develop final guideline

•

Discuss final guideline with CCE for implementation

•

Develop and present summary of results to Millennium Global Medical Affairs
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Appendix E
Subcutaneous Adm inistration o f Bortezom ib Survey

Sponsor of Survey: Jasmine Martin, MSN, APRN
303-973-5768
Purpose: The purpose o f this survey is to understand oncology nurses practice, opinion and
perceptions about administering subcutaneous bortezomib at Cancer Clinics of Excellence. This
survey is being done in partial fulfillment for a Doctor of Nursing program at Regis University.
The information that is gained from your participation will be used to contribute to oncology
nursing practice and provide information about content needed for developing a standardized
guideline for administering subcutaneous bortezomib at Cancer Clinics of Excellence. This
project may improve patient care and quality outcomes by reducing injection site reactions and
pain for patients receiving subcutaneous bortezomib. Information from the project may be used
in future presentations or publications.
All of your responses will be anonym ous and confidential; no identifying information will be
linked to you in any way.
Participation: You have been selected to participate in this survey because you have
administered subcutaneous bortezomib in 2012. Your participation is voluntary. By completing
this survey you consent to participate. If you choose not to participate, simply do not complete
the survey. There is no consequence to your position or practice for not participating; you will
not be compensated for your participation.
Directions:
• This survey will take approximately 20 minutes to complete.
• Please answer each question as completely as possible based on your own experience
with, and opinion or perception about administering subcutaneous bortezomib.
• Most questions are multiple choices.
• Some questions request a brief, concise explanation for your response.
• There are no right or wrong answers; the purpose is to describe your personal practice,
opinion and perception.
Thank you again for your participation in this survey.

Section I
Questions 1 - 6 ask about your oncology and nursing experience. All information will be
aggregate; no information can be linked directly to the participants.
1. Highest nursing degree I have earned is:
a. ADN
b. BSN
c. MSN
d. MSN, NP
e. MSN, CNS
f. DNP
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g. PhD Nursing
Other degree - please describe
2. I am certified by the Oncology Nursing Certification Corporation (ONCC) or other
nursing certification organization as: (check all that apply)
a. I am not certified by a credentialing organization
b. OCN
c. AOCNP
d. AOCNS
e. AOCN
f. CPHON
g. CBCN
h. APRN - BC
Other - please describe
3. I have been practicing oncology nursing for
a. Less than 1 year
b. 1-5 years
c. 6 - 10 years
d. 11- 20 years
e. > 20 years
4. I have
a.
b.
c.
d.
e.

been in nursing for
Less than 1 year
1-5 years
6 - 10 years
11- 20 years
> 20 years

5. Gender
a. Male
b. Female
6. My age is
a. Less than 21 years old
b. 21-29 years old
c. 30-39 years old
d. 40-49 years old
e. 50-59 years old
f. 60 or older
Section II
Questions 7 - 28 ask about your personal experience administering subcutaneous
bortezomib in the clinic. Please choose the answer that most closely describes your
experience and explain your answer when requested.
7. Who is responsible for ordering bortezomib will be administered by the subcutaneous
route? (Circle all that apply)
a. Oncologist
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b. Nurse Practitioner
c. Clinical Pharmacist
8. Are you able to provide input into the decision regarding route of administration for
delivering bortezomib to patients?
a. Always
b. Sometimes
c. Rarely
d. Never
9. To approximately how many patients do you administer subcutaneous bortezomib
in a month?
a. 1 - 5
b. 6 - 10
c. More than 10
10. To approximately how many patients do you administer intravenous bortezomib in a
month?
a. 1 - 5
b. 6-10
c. More than 10
11. How often are you responsible for the reconstitution/preparation of bortezomib?
a. Always
b. Sometimes
c. Rarely
d. Never
12. What anatomical sites do you use to administer subcutaneous bortezomib? (circle all
that apply)
a. Abdomen
b. Thigh
c. Arm
13. What
a.
b.
c.

site do you prefer to administer subcutaneous injections of bortezomib?
Abdomen
Thigh
Arm

14. Why do you prefer the above site for injections?
15. Do you document site of injection?
a. Yes
b. No
16. How do you rotate SC injection sites?
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a. Rotate to different anatomical sites (ie abdomen to thigh and thigh to
abdomen)
b. Rotate injection sites within same anatomical area (ie rotate injections on the
abdomen)
c. Rotate per nurses discretion (no designated pattern of injection site rotation)
d. No rotation of injection site, use site previously used
17. Do you have an anatomical map in the patient chart to guide site rotation for each
injection?
a. Yes
b. No

18. What site preparation do you use prior to administering the injection? (check all that
apply)
a. Ice
b. Alcohol prep
c. EMLA cream
d. None
e. Other - please describe
f.
19. What
a.
b.
c.
d.

size needle do you use for administering the subcutaneous injection?
25 gauge needle that is 5/8 inch or shorter
25 gauge needle that is longer than ^ inch in length
W hat ever needle the reconstituted drug comes with
Unsure

20. Do you routinely put a new needle on the syringe before administering the injection?
a. Yes
b. No
21. What angle do you use to administer the SC injection when using a 4 - 6 mm needle?
a. 45 degree
b. 90 degree
22. What angle do you use to administer the SC injection when using a >6 mm needle?
a. 45 degree
b. 90 degree
23. What do you do to inject into adipose tissue
a. Pinch the skin to a tent
b. Administer in fatty areas
c. Other
Please describe
24. Prior to injecting the drug do you
a. Expel air from the syringe
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b. Pull air into the syringe
Please explain your rationale
25. Approximately how long does it take to administer each ml of subcutaneous
bortezomib injection?
a. 3 - 5 seconds
b. 5 - 10 seconds
c. 10-30 seconds
d. More than 30 seconds
e. It depends on (explain)
f.
26. Do you routinely apply pressure to the site after the injection?
a. Yes
b. No
27. Does this oncology clinic have a standard guideline for administering subcutaneous
bortezomib?
a. Yes
b. No
c. Unsure
28. The technique you use to inject subcutaneous bortezomib is based on (check all that
apply):
a. My clinical experience
b. Clinical practice guidelines
c. Demonstration from colleagues
d. In-service or education seminar - please describe
e. Other - please describe
Section III
Questions 29 - 38 explore your opinion about administering subcutaneous bortezomib.
Please choose the answer that most closely describes your opinion and explain your answer
when requested.
29. Overall, is there a difference in the time it takes to administer subcutaneous versus
intravenous bortezomib?
a. Much less time for subcutaneous
b. Somewhat less time for subcutaneous
c. Somewhat more time for subcutaneous
d. Much more time for subcutaneous
Please explain your answer
30. Overall, in your clinical opinion, is the subcutaneous route more or less convenient
for nurses to administer than the intravenous route?
a. Subcutaneous is much more convenient
b. Subcutaneous is somewhat more convenient
c. Subcutaneous is somewhat less convenient
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d. Subcutaneous is much less convenient
Please explain your answer
31. For patients who have received both intravenous and subcutaneous bortizomib, what
route of administration do you believe patients prefer?
a. Prefer intravenous
b. Prefer subcutaneous
c. No preference
Please explain you answer
32. For patients receiving subcutaneous bortezomib, what site do you believe they
generally prefer for the injections?
a. Abdomen
b. Thigh
c. Arm
33. Why do you believe patients generally prefer the above site for injections?
34. In your clinical opinion, do privacy concerns for patients receiving the injection
influence subcutaneous injection site selection?
a. Yes
b. No
c. Please explain
35. What is the layout in your facility where subcutaneous injections are primarily
given?
a. Private examination room
b. Open infusion suite with chairs
c. Open infusion suite with curtains around each chair
d. Nurses station
e. Other: please describe
36. Your clinical decision determines where to administer subcutaneous bortezomib
injections
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
37. The patient’s preference determines where to administer subcutaneous bortezomib
injections
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
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38. If your technique for administering subcutaneous bortezomib differs from a practice
guideline developed by Cancer Clinics of Excellence (CCE), you would change your
technique to be consistent with the guidelines
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
Please explain your answer
Section IV
Questions 39-44 are about your practice setting and your perception of the practice. Please
choose the answer that most closely describes your perceptions. Because these questions
explore your perceptions, please briefly explain your answers.
39. All the nurses in this clinic use the same technique to administer subcutaneous
bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree
Please explain your answer
40. It is important to patients that all nurses follow the same technique when
administering subcutaneous bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree
Please explain your answer
41. Patients have noticed and commented that there are differences in techniques
between nurses administering subcutaneous bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree
Please explain your answer
42. It is important to the physician(s) that all nurses follow the same technique when
administering subcutaneous bortezomib.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Completely disagree
Please explain your answer

43. A practice guideline is important in this clinic to standardize how and where
subcutaneous bortezomib will be administered.
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a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
Please explain your answer
44. If other nurses in this clinic are using techniques for administering subcutaneous
bortezomib that differed from a CCE practice guideline, they would change their
techniques to be consistent with the guidelines.
a. Completely agree
b. Somewhat agree
c. Somewhat disagree
d. Disagree completely
Please explain your answer
Thank you again fo r your time and consideration to these questions.
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Appendix F
Institutional Board Approvals and CITI Certificate
Approval of Submitted Proposal...
Institutional Review Board
This message was sent with High importance.
You forwarded this message on 5/16/2013 5:01 PM.
Sent:Thursday, May 16, 2013 3:36 PM
To: Martin, Jasmine R
Cc: Ernst, Diane M; Gilbert, Marcia a.; Institutional Review Board
Dear Ms. M artin...

The Institutional Review Board has thoroughly reviewed your protocol submission,
supplementary materials, and site approval letter for your study entitled Subcutaneous
Administration o f Bortezomib Practice Improvement Project. I am pleased to inform you that
the study has been approved as an Exempt proposal per Category # 2. You may begin study
implementation and data collection upon receipt of this email. An official letter of approval for
your study files will be forthcoming. We wish you success with your planned investigation!

Patsy McGuire Cullen, PhD, CPNP
Chair, Institutional Review Board
(303) 964-5132
pcullen@regis.edu
irb@regis.edu

For IRB - Summary Paragraph outlining an Evidence Based Practice Project
This project is an evidence-based practice (EBP) project in which a quality improvement plan,
program evaluation, or simple educational or standard of care intervention (with a pre-test and
post-test evaluation) will be completed. The project will be internal to an agency and inform the
agency of issues in health care quality, cost, and satisfaction. The results from this project are not
meant to generate new knowledge or be generalizable across settings but address a specific
population, at a specific time, in a specific agency. These projects translate and apply the science
of nursing to the health care field. EBP Projects utilize the acronym “PICO” rather than using a

Subcutaneous Bortezomib

121

hypothesis. PICO stands for: P - Population or disease; I - Intervention or Issue of Interest; C Comparison or Current Practice; and O - Outcome. Some PICO projects will not include the
“C.” Each PICO can be written in the form of a question and will use this template to write the
question: I n ___ Oncology nurses in the Cancer Clinics o f Excellence Network who have
administered Subcutatnous bortezomib_____________ (P), how does __ techniques in a practice
guideline_________________ (I) compared to/with ___ current practice as describedfrom survey
results____________________ (C) affect/influence/predict
adoption o f a practice
guideline________________ (O)? (Melnyk & Fineout-Overholt, 2011, p. 31)

April 9, 2013
Jasmine Martin, MSN
Cancer Clinics of Excellence
5750 DTC Parkway Suite 101
Greenwood Village, CO
RE: NEIRB# 13-131: "Subcutaneous Administration of Bortexomib: A Nurse Survey"
Dear Ms. Martin:
This is to inform you that New England Institutional Review Board (NEIRB) has reviewed the
claim of exemption for the above-captioned project. NEIRB has determined that this research
activity, as conducted at the above location, is exempt from NEIRB review, under the following
categories:
□ Research involving the use of survey procedures or interview procedures or observation of
public behavior for which subjects cannot be identified, OR release of the information would not
be harmful to the subject.

Amendments and or changes to the research must be submitted to NEIRB for review, as changes
may affect the exempt status.
Please call me if you have any questions about the terms of this determination.
Erin Brower, MS, CIP
Director
Copy: NEIRB Chair
Traci Kalberer, Cancer Clinics of Excellence
85 Wells Avenue . Suite 107 . Newton, MA 02459 Phone: 617-243-3924 . Fax: 617-9691310 www.neirb.com
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CITI Collaborative Institutional Training Initiative
Human Research Curriculum Completion Report
Printed on 7/24/2013
Learner: Jasmine Martin (username: jasminemartin)
Institution: Regis University
Contact Information 1921 W Sanibel Ct
Littleton, CO 80120
Department: Nursing, DNP program
Phone: 303-973-5768
Email: jasminemartin@comcast.net
Social Behavioral Research Investigators and Key Personnel:
Stage 1. Basic Course Passed on 08/04/12 (Ref # 8400736)
Required Modules
Date
Completed
Introduction 08/04/12 no quiz
History and Ethical Principles - SBE 08/04/12 4/5 (80%)
The Regulations - SBE 08/04/12 5/5 (100%)
Assessing Risk - SBE 08/04/12 5/5 (100%)
Informed Consent - SBE 08/04/12 5/5 (100%)
Privacy and Confidentiality - SBE 08/04/12 4/5 (80%)
Regis University 08/04/12 no quiz
For this Completion Report to be valid, the learner listed above must be
affiliated with a CITI participating institution. Falsified information and
unauthorized use of the CITI course site is unethical, and may be
considered scientific misconduct by your institution.
Paul Braunschweiger Ph.D.
Professor, University of Miami
Director Office of Research Education
CITI Course Coordinator
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Appendix G
Permissions and Agency Letters of Support

RE: Request for permission to use graphics in a CDA publication
CaroleAnn Maloney [caroleann_maloney@bd.com]
You replied on 7/12/2013 8:25 AM.
Sent:
Wednesday, July 10, 2013 11:15 AM
To:
Martin. Jasmine R
U d ERMEPLI SER45 Office.iou (199 KB): i J PLI-INCORRECT Office.jpg
(120 KB): B p l i -CORRECT Office.jpg (106 KB): U P N sizes Press.jpg (2
Attachments: ^ ^

i j iNJ ZONESHF Office.jpg (142 KB): U FIT figure 10 (skin

thickn~l.JPG (48 KB):
site rotation scheme FIT.PNG (261 KB): LJ
BD4181 FIT CANADA pg!4 ILL.jpg (238 KB)
Yes, you have our permission to use these photos with the following credit: Photos courtesy of
Forum for Injection Technique (FIT) Canada 2013
See attached the requested photos.
Good luck!

CaroleAnn Maloney, RD, CDE
Clinical Education Specialist
BD Medical - Diabetes Care
2100 Derry Rd. W, Suite 100 Mississauga, ON L5N 0B3
Office: 905-288-6246 Mobile: 905-965-0838 Fax: 905-288-6006
Email: CaroleAnn_Maloney@bd.com Website: www.BD.com

RE: Request to use TPB diagram
Icek Aizen [aizen@psych.umass.edu]
Sent:Wednesday, December 05, 2012 7:03 AM
To: Martin, Jasmine R
Dear Jasmine Martin,
The theory of planned behavior is in the public domain. No permission is
needed to use the theory in research, to construct a TPB questionnaire, or
to include an ORIGINAL drawing of the model in a thesis, dissertation,
presentation, poster, article, or book. If you would like to reproduce a
published drawing of the model, you need to get permission from the
publisher who holds the copyright. You may use the drawing on my website
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(http://www.people.umass.edu/aizen/tpb.diag.html) for non-commercial
purposes so long as you retain the copyright notice.
Best regards,
Icek Ajzen, Professor Emeritus
University of Massachusetts
Amherst, MA 01003
http://www.people.umass.edu/aizen
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RE: Request regarding The Neutropenia Oncology Nurses Survey
Anita Nirenberg [anirenbe@hunter.cuny.edu]
You forwarded this message on 12/11/2012 11:17 AM.
Sent:
Tuesday, December 11, 2012 9:43 AM
To:
Martin, Jasmine
Attachments:
NONS survev.doc (57 KBUOpen as Web Page!
Hi Jasmine,
So, here it comes.
I would like to see how you're adapting the instrument and that you will give proper
acknowledgement (I know that you will).
Take good care of my "baby".
Good luck
Anita
Anita Nirenberg DNSc, RN, PNP, BC, AOCNP
William Randolph Hearst Professor of Clinical Nursing
Hunter-Bellevue School of Nursing, Hunter College
City University of New York
425 East 25th St
New York, NY. 10010
212 481-4359: email:anirenbe@hunter.cuny.edu

125

126

Subcutaneous Bortezomib

■

CANCER
C L IN IC S O F
E X C E LLE N C

Jasm ine Martin, MSN, APRN
1921 W Sanibel Ct.
Littleton, CO 80120
May 2, 2013
Dear Jasm ine,
Cancer Clinics of Excellence (CCE) Is a network of tw enty-tw o com m unity
based Medical O ncology practices from fourteen unique states. The m ission of
our network is to provide evidence based, personalized care to patients in their
com m unity. Our practices participate in clinical trials and studies to im prove care
and provide cutting edge treatm ents for our patients.
Your request to survey nurses (RNs) within our network adm inistering SC
bortezom ib (Velcade), and describe their opinions and perceptions of SC
bortezom ib is approved. Wo hope that the Insight provided will assist in
im proving patient care, patient experience and clinical outcome.
CCE would like to review any presentations or publications created that
reference CCE or are based on the CCE survey data prior to final presentation or
publication.
CCE supports your efforts and we look forward to sharing im provem ent
opportunities with our practice staff.
Please feel free to contact me if you have additional inform ation needs.
Sincerely,

Nancy Beegle
Cancer Clinics of Excellence
VP of Clinical O perations
nbeBKlg@ ccg.us .com
303-220-9951

From: Solomon, Stefanie
To: nbeegle@cce.com
Cc: Martin, Jasmine
Subject: Millennium Study
Date: Wednesday, May 01, 2013 6:41:35 PM
Ms. Beegle,
This note is in regard to the subcutaneous bortezomib nursing survey sponsored by Millennium
Pharmaceuticals. In addition to the corporate use o f the survey data, we are aware that Jasmine
Martin, DNPc, MSN, will be using these data as part of her doctoral program at Regis
University.
Please let me know if you have any questions.
Best regards,
Stefanie Solomon
Sr Counsel
Millennium Pharmaceuticals, Inc.
The Takeda Oncology Company
40 Landsdowne Street
Cambridge, MA 02139
Ph:(617) 551-2948
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Appendix H
The Subcutaneous Administration of Bortezomib Practice Guideline

Cancer Clinics of Excellence

Subcutaneous Bortezomib

128

Date Issued: July 10, 2013
Last Revised: July 31, 2013 by Jasmine Martin, DNP, MSN, APRN
Approved by:
DISCLAIMER: THE PROCEDURE DESCRIBED DOES N O T REFLECT THE
MANUFACTURER (MILLENNIUMPHARMACEUTICALS, THE TAKEDA ONCOLOGY
COMPANY) RECOMMENDATIONS FOR ADMINISTERING SUBCUTANEOUS
BORTEZOMIB.
The procedure is based on evidence from the clinical literature and a survey of nurses as
part of an academic project.
Pages: 22 (including references)
Rationale, Purpose and Outcomes:
The Cancer Clinics of Excellence (CCE) network is committed to delivering proven,
evidence-based treatment to people with cancer. This evidence based treatment protocol (ETP)
provides Registered Nurses (RNs) with guidelines on the administration of subcutaneous
bortezomib (SCB). The guideline is based on evidence in the clinical literature on administration
of subcutaneous injections and from a survey of 43 nurses in the CCE network describing current
SCB injection techniques as well as their opinions about SCB.
Bortezomib (Velcade) is an effective treatment for patients with multiple myeloma
(Driscoll, Burris, & Annunziata, 2012). The subcutaneous (SC) route of administration has been
shown to be equally efficacious as the intravenous (IV) route, but with less peripheral
neuropathy (PN). Clinical studies and the package insert on SCB described the concentration for
preparing the drug and that the injections were administered in the abdomen and thigh (Arnulf et
al. 2012; Moreau et al. 2011; Moreau et al. 2012; Velcade 2012). A retrospective study o f 15
patients suggested higher incidence of injection site reactions in the thigh than abdomen
(Kaminura et al. 2012). Studies of SCB and the package insert do not describe how the injections
were administered.
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The clinical literature is inconclusive on the best way to administer SC injections in
general (Annersen & Willman, 2005). However, clinical studies have shown needle size, angle
of injection, use of an air bubble and giving injections over 10 to 30 seconds have resulted in
decreased bruising, site reactions and increased patient satisfaction (Birkebaek, Solvig,
Jorgensen, Smedegaard, & Christiansen, Frid et al. 2010; Gibney, Arce, Bryon & Hirsch, 2010;
Gill & Prausnitz, 2007; Moore et al. 2010; Wooldridge & Jackson, 1988; Zaybak & Korshid
2007).
A 2013 survey of 43 CCE RNs who had administered SCB suggested there is agreement
that SCB is more convenient than IVB and nurses believe patients prefer SCB to IVB. There
were differences in techniques used and generally strong agreement that a practice guideline
would be beneficial and would be followed by CCE nurses.
The purpose for a guideline is to provide RNs at CCE with a standardized method for
administering SCB. The expected outcome of implementation and adoption of a practice
guideline by oncology RNs is to specifically impact the nursing sensitive outcomes of patients
with multiple myeloma. Nursing sensitive patient outcomes (NSPO) are those outcomes that can
be influenced directly by nursing interventions (Given & Sherwood, 2005). Oncology NSPOs
that may be realized with consistent SC injection techniques include:
Table 11 Nursing Sensitive Patient Outcomes and Measures
Outcome
Symptom control and management

Measures
•
•

Functional status

•

Psychological health status

•

Lower incidence of peripheral
neuropathy
Reduced injection site reactions and
pain
Completion of effective treatment
length of therapy
Reduced discomfort and anxiety
associated with injection and treatment
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•
•
•
•

Economics

Patient perception about treatment
Reduced clinic time
Reduced cost
Cost effective treatment compared to
other treatment options

Responsible:
All RNs in the CCE network who administer bortezomib by the subcutaneous route to
patients.
Abbreviations:
CCE

Cancer Clinics of Excellence

ETP

Evidence Based Treatment Protocol

IV

Intravenous

IVB

Intravenous bortezomib

NSPO Nursing Sensitive Patient Outcomes
RN

Registered Nurse

SC

Subcutaneous

SCB

Subcutaneous bortezomib
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Guideline Procedure:
Graphics used with permission courtesy o f Forum for Injection Technique (FIT) Canada 2013
Procedure

Rationale and References

Verify order and appropriate dilution

Bortezomib can be administered either by
the intravenous or subcutaneous route.
For subcutaneous route of
administration:
The volume of 0.9% sodium
chloride used to reconstitute
VELCADE for subcutaneous
administration is less than the
volume used for IV administration

for the route of administration ordered.

— For
subcutaneous
reconstitution, add 1.4 mL
of sterile 0.9% sodium
chloride solution to the
powder contained in the
vial of VELCADE
— This
reconstitution will result in
a final concentration of 2.5
mg/mL VELCADE
— The
reconstituted product
should be a clear and
colorless solution free of
particulate matter
▼ Apply stickers to the vial and syringe
that identify the intended route of
administration
For intravenous route of administration:
The volume of 0.9% sodium
chloride used to reconstitute
VELCADE for IV adm in istration
is greater than the volume used for
subcutaneous administration
— For IV
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reconstitution, add 3.5 mL
of sterile 0.9% sodium
chloride solution to the
powder contained in the
vial of VELCADE
— This
reconstitution will result in
a final concentration of 1
mg/mL VELCADE
— The
reconstituted product
should be a clear and
colorless solution free of
particulate matter
▼
Apply stickers to the vial
and syringe that identify the
intended route of administration
(Velcade package insert, 2012)
(Level of Evidence II)
2. Review procedure and rationale with
patient
3. Select appropriate site for

Clinical studies only administered SCB

administration and rotation ( See

in the abdomen and thigh, rotating

Figures 1, 2 and 3). If patient has had

between sites with each injection

prior SCB injection(s), inspect prior

(Moreau et al, 2011; Moreau et al. 2012;

site(s) and document current condition

Arnulf et al. 2012). There is no data on

and patient report of previous

administering SCB in the arm. One

injection(s) site(s) and experience(s).

study reported more injection site

Inject at least 1 inch from prior injection

reactions in the thigh than abdomen

sites

with SCB (Kaminura et al. 2012). CCE
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nurses indicated preference for using the
abdomen. If only the abdomen is used,
rotate the location to a different
quadrant on the abdomen with every
injection (See Figure 1). Within the
quadrants on the abdomen, injections
should be at least 1 inch from any prior
injections (See Figure 2).
(Level of Evidence V)

Figure 1. Abdominal Injection Sites and Rotation
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Figure 2. Rotations within abdominal quadrants

Figure 3 Site Rotation Thighs

4. Place new needle on syringe

Use of a dry needle ensures bevel has not
been dulled when inserted into the vial
and eliminates tracking drug when
inserting the needle into the skin (Agac
& Gunes 2011)
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(Level of Evidence II)

5. Pull air into syringe to create an air

Randomized studies with SC interferon

bubble (See Figure 4). “ Applying a fresh

and heparin have shown use of an air

non-primed needle to the syringe with

bubble (air sandwich) technique resulted

bortezomib, then drawing in an additional

in significantly less bruising, pain, and

0.5 to 1 mm of air, inverting the needle,

injection site reactions and improved

and injecting” (Kurtin, 2013).

patient satisfaction and compliance

NOTE: This technique is never to be used

(Moore, 2007; Wooldridge & Jacson

with Intravenous injections.

1988). The air sandwich technique has
been recommended by the International
Myeloma Foundation, and may prevent
tracking drug when inserting and
removing the needle (IMF, 2012; Kurtin,
Knop & Milliron, 2012; Kurtin 2013;
Kurtin S. n.d.; Murray et al. 2012)
(Level of Evidence III for Moore et al. &
Wooldridge & Jackson. Level VII for
Kurtin and IMF)
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Figure 4 Air Bubble Technique

6. Wash hands, put on clean gloves, and

Prevent contamination and cross

clean injection site

contamination from staff to patient
(Hunter 2008)

7. Pinch tissue with thumb and index

Skin thickness does not vary

finger (See Figures 5 and 6)

significantly in adults, whereas
subcutaneous adipose tissue does vary in
different anatomical sites, between
genders, with increased body mass index
(BMI) and waist circumference (Akkus
et al 2012; Gibney et al. 2010). Pinching
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tissue helps ensure injection will be in
adipose tissue and not into muscle. Using
thumb and index finger may reduce
grasping muscle tissue
(Level of Evidence III)

Figure 5 Correct Skin Lift: Pinch Skin with Thumb and Forefinger

Figure 6 Incorrect Skin Lift: Avoid Grasping Muscle Tissue
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8. Insert needle with smooth, steady

There is consistency in describing

motion using 45 degree angle when using

the angle of insertion to ensure entering

a needle longer than 6 mm

subcutaneous tissue rather than risking

NOTE: Angle of insertion is dependent

intramuscular (IM) injections based on

on needle length. (See Figures 6 and 57)

needle size. A study of 388 adult

Needle length Conversion:

diabetics demonstrated small needles,

4 mm = 5/32 inch

4mm to 6 mm in length, inserted at a 90

5 mm = 3/16 inch

degree angle without raising a skin fold

6 mm = 1/4 inch

will be in the SC tissue more than 98%

8 mm = 5/16 inch

of the time. Needles 6mm to 8 mm

9.5 mm = 3/8 inch

inserted at 90 degrees will result in IM

12.7 mm = 1/2 inch

injections 5% and 15% of the time. A

15.8 mm = 5/8 inch

12.7mm (1/2 inch) needle will result in
IM injections 45% of the time when
inserted at 90 degree angle and 21% of
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the time when inserted at 45 degree
angle (Gibney, Arce, Bryon, & Hirsch,
2010). A study of 499 subjects, including
297 healthy controls, suggested the use of
longer needles (> 6mm) without pinching
the skin or inserting at a 90-degree angle
might result in an IM injection (Akkus et
al., 2012).
(Level of Evidence III)

Figure 7 Proper Injection Technique for 45 Degree Angle Insertion into Skin Lift. To be
used with Needles Longer than 6 mm (1/4 inch)

Figure 8 Proper Injection Technique for 90 Degree Angle Insertion into Skin Lift (depicted
right). 90 degree angle is to be used with needles 6mm or shorter. 90 Degree Insertion
without a skin lift (depicted left) may result in IM injection.
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9. Inject medication slowly over 10 - 30

Slow injections can reduce tissue damage

seconds. Use a minimum injection time of

caused by increased pressure.

10 seconds per ml.

Experimental studies on SC injection
duration demonstrated 30-second SC
injections resulted in statistically
significantly less pain and bruising than
10-second injections (Akpinar &
Celbioglu, 2007; Chan 2001; Zybak &
Khorshid, 2007).
(Level of Evidence III)

10. Wait briefly before withdrawing the

Prevent backflow of medication.

needle.

(Akpinary & Celebioglu, 2006; Hunter
2008)
(Level of Evidence IV)

11. Apply gentle pressure with dry
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gauze, and do not massage site.
12. Assess site.
13. Document site of administration in
chart. Use anatomical site chart if
available.
14. Instruct patient to report any

Patient education about safety is a core

unusual redness, swelling, warmth.

professional role. Having oncology

Reinforce teaching on side effects to

patients involved in preventing

monitor and report.

treatment errors and identifying adverse
events results in trustful relationships
(Schwappach, Hocreutener & Wernli
2010).
(Level of Evidence VI)

Summary of guideline for administering SC bortezomib:

1. Use small gauge short needles.
2. Change the needle on the syringe before administering the injection.
3. Add an air bubble to the syringe to create an air sandwich.
4. Use a skin lift to ensure injection into adipose tissue.
5. Inject at a 45-degree angle into a skin lift for needles longer than 6mm (1/4 inch). A 90
degree angle may be used into a skin lift for needles shorter than 1/4 inch.
6. Inject slowly, over 10 to 30 seconds.
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7. W ait briefly before withdrawing the needle.
The techniques described in this guideline are based on evidence from the clinical literature.
Levels of evidence are from M elnyk’s Hierarch of Evidence (Table 2).

Table 2 Melnyk's Hierarch of Evidence (2005)
Description

Strength

Evidence from a systematic

Strongest

Level of Evidence
I

review or meta-analysis of all
relevant randomized controlled
trials (RCT), or evidence - based
clinical practice guidelines based
on systematic review of RCTs
II

Evidence from at least one welldesigned RCT

III

Evidence from well-designed
controlled trials without
randomization

IV

Evidence from well designed casecontrolled and cohort studies

V

Evidence from systematic reviews
of descriptive and qualitative
studies
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Evidence from a single descriptive
or qualitative study

VII

Evidence from the opinion of

Weakest

authorities and/or reports of
expert committees
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